

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Factors Associated with Inpatient Length of Stay among Hospitalized Patients with Chronic Obstructive Pulmonary Disease, China, 2016-2017: a retrospective study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-040560
Article Type:	Original research
Date Submitted by the Author:	16-May-2020
Complete List of Authors:	<p>Dong, Fen; Institute of Clinical Medical Sciences, China-Japan Friendship Hospital,</p> <p>Huang, Ke; China-Japan Friendship Hospital, Department of Pulmonary and Critical Care Medicine; National Clinical Research Center for Respiratory Diseases</p> <p>Ren, Xiaoxia; China-Japan Friendship Hospital, Department of Pulmonary and Critical Care Medicine; National Clinical Research Center for Respiratory Diseases</p> <p>Qumu, Shiwei; China-Japan Friendship Hospital, Department of Pulmonary and Critical Care Medicine; National Clinical Research Center for Respiratory Diseases</p> <p>Niu, Hongtao; China-Japan Friendship Hospital, Department of Pulmonary and Critical Care Medicine; National Clinical Research Center for Respiratory Diseases</p> <p>Wang, Yanyan; China-Japan Friendship Hospital, Department of Medical Records</p> <p>Li, Yong; China-Japan Friendship Hospital, Department of Pulmonary and Critical Care Medicine; National Clinical Research Center for Respiratory Diseases</p> <p>Lu, Minya; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Department of Clinical Laboratory</p> <p>Lin, Xinshan; China-Japan Friendship Hospital, Department of Pulmonary and Critical Care Medicine; Chinese Academy of Medical Sciences & Peking Union Medical College, Graduate School of Peking Union Medical College</p> <p>Yang, Ting; China-Japan Friendship Hospital, Department of Pulmonary and Critical Care Medicine; National Clinical Research Center for Respiratory Diseases</p> <p>Jiao, Jianjun; China-Japan Friendship Hospital, Department of Medical Administration</p> <p>Wang, Chen; China-Japan Friendship Hospital, Department of Pulmonary and Critical Care Medicine; Chinese Academy of Medical Sciences & Peking Union Medical College</p>
Keywords:	Chronic airways disease < THORACIC MEDICINE, Epidemiology < THORACIC MEDICINE, Risk management < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Factors Associated with Inpatient Length of Stay among**
4
5
6 **Hospitalized Patients with Chronic Obstructive Pulmonary**
7
8 **Disease, China, 2016-2017: a retrospective study**
9

10
11 Fen Dong¹, Ke Huang², Xiaoxia Ren², Shiwei Qumu², Hongtao Niu², Yanyan Wang³, Yong
12
13 Li², Minya Lu⁴, Xinshan Lin^{2,5}, Ting Yang^{2*}, Jianjun Jiao^{6*}, Chen Wang^{2,7}
14
15

16
17 ***Co-corresponding authors:** Ting Yang and Jianjun Jiao contributed equally to this
18
19 paper as co-corresponding authors.
20
21

22
23
24 **Affiliations:**
25

26 ¹Institute of Clinical Medical Sciences, China–Japan Friendship Hospital, Beijing, China;
27

28 ²Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital;
29
30 National Clinical Research Center for Respiratory Diseases; Institute of Respiratory
31
32 Medicine, Chinese Academy of Medical Science, Beijing, China;
33

34 ³Department of Medical Records, China–Japan Friendship Hospital, Beijing, China;
35

36 ⁴Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese
37
38 Academy of Medical Sciences, Beijing, China;
39

40 ⁵Graduate School of Peking Union Medical College, Chinese Academy of Medical
41
42 Sciences & Peking Union Medical College, Beijing, China;
43

44 ⁶Department of Medical Administration, China–Japan Friendship Hospital, Beijing,
45
46 China;
47

48 ⁷Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
49
50

51
52
53 **Correspondence:** Ting Yang
54
55
56

1
2
3 Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital;
4
5 National Clinical Research Center for Respiratory Diseases; Institute of Respiratory
6
7 Medicine, Chinese Academy of Medical Science. No 2, East Yinghua Road, Chaoyang
8
9 District, Beijing, China
10

11 Tel : +010 8420 6273

12
13 Email : dryangting@qq.com
14
15

16
17
18 **Word count** : 2613, excluding the title page, abstract, tables, acknowledgements,
19
20 contributions and references.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives: To identify factors associated with length of stay (LOS) in Chronic obstructive pulmonary disease (COPD) hospitalized patients, which may help shorten LOS and reduce economic burden accrued over hospital stay.

Design: A retrospective cohort study

Setting: This study was performed in a tertiary hospital in China.

Participants: New COPD patients who were aged ≥ 40 years and admitted between 2016 and 2017.

Primary and secondary outcome measures: LOS at initial admission was the primary outcome and health expenditures were the secondary outcome. To identify factors associated with LOS, we collected information at index hospitalization and constructed a conceptual model using directed acyclic graph (DAG). Potential factors were grouped into five blocks: demographic information, disease severity, comorbidities, hospital and environmental factors. Negative binomial regression model was fitted for each block of factors and then a parsimonious analysis was performed.

Results: Totally, we analyzed 565 COPD patients. The mean \pm SD age was 69 \pm 11 years old and 69.4% were male. The median LOS was 10 days with an interquartile range of 8-14 days. In modelling each block of factors, venous thromboembolism (rate ratio [RR] =1.38, 95% confidence interval (CI): 1.07-1.76), pulmonary encephalopathy (RR=1.53, 95%CI: 1.06-2.20), respiratory infection (RR=1.12, 95%CI: 1.01-1.24), osteoporosis (RR=1.45, 95%CI: 1.07-1.96), and emergence admission (RR=1.08, 95%CI: 1.01-1.16) were associated with longer LOS. In parsimonious analysis, all the aforementioned factors remained significant except emergency admission, strengthening their associations with hospital stay. Additionally, total hospitalization cost and patients' out-of-pocket cost increased monotonically with LOS (both $P_{\text{trend}} < 0.0001$).

1
2
3 **Conclusion:** Patients' concomitant morbidities predicted excessive LOS in COPD
4 patients. Hospitalization healthcare cost increased over the length of stay. Quality
5 improvement initiatives may need to identify patients at high risk of longer stay and
6 implement early interventions such as thromboprophylaxis to avoid lengthy stay, which
7 could help reduce the high economic burden of COPD.
8
9
10
11
12

13
14
15
16 **Keywords:** Pulmonary disease, Chronic obstructive; Length of Stay; Risk Factors; DAG
17
18
19

20 **Article Summary**

21 **Strengths and limitations of this study**

- 22 ● LOS and economic burden were analyzed in newly admitted COPD patients in
23 developing countries.
- 24 ● The primary data analysis was based on conceptual model and theoretical model
25 driven
- 26 ● Real experiences of hospitalized patients in the real-world clinical setting were
27 analyzed
- 28 ● Analysis in this single center study may not reflect the comprehensive profile of LOS
29 in Chinese patients.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is a burdensome chronic respiratory disease. It's estimated to cause 2.6% Disability-Adjusted Life Years (DALYs) globally and ranked as the third top cause of DALYs in China.¹ The prevalence of COPD in Chinese adults is 8.6%, with approximately 100 million COPD patients.² People aged over 40 years are particularly at high risk due to its onset in later life. During COPD progress, acute worsening respiratory symptoms can be easily triggered,^{3,4} leading to hospitalizations and increased use of health service.⁵ Spending on hospital-based care constitute the major healthcare cost in COPD patients, accounting for 65.9%-77% of medical costs in China.^{6,7} The direct medical cost of COPD was estimated at \$1732.24 per patient annually in 2006^{8,9} and hospitalization cost per admission increased to \$3669.33 in 2016.¹⁰ COPD is also a costly disease in developed countries. In US, it consumes \$72 billion in direct healthcare cost each year¹¹ and the tremendous cost is projected to be on the rise.^{11,12} Given the large prevalent population and substantial economic burden imposed by COPD, interventions targeted to hospitalization are needed. Hospital stay is an important outcome for health care systems¹³ and indicates the acute impact of exacerbation on patients.¹⁴ Length of stay (LOS) correlates with hospitalization cost.¹⁵ Shortening LOS might be one way to slow down the escalating healthcare cost.

Owing to disparities in healthcare systems or service use, there exists a high heterogeneity of LOS across countries.^{12,16,17} In China, some patients stay longer under certain circumstances, eg, discharged and readmitted on the same day due to complicated conditions, prolonging their actual stay for the same hospitalization. Two prior studies in Chinese COPD patients demonstrated that respiratory coinfection and eosinopenia were associated with longer stay.^{14,18} However, these studies focused more on single exposure-outcome relationship between one risk factor of interest and LOS. The lengthy stay is multifactorial and a diversity of factors can contribute to prolonged LOS, such as poor

1
2
3 patients' health status, complicated disease conditions, and organization operation et
4 al.^{17,19-22} Some of these factors are related to health system and some are at patient level.
5
6
7 To effectively reduce LOS and COPD disease burden, it's of paramount importance to
8
9 identify important factors associated with LOS.
10

11 Thus, we conducted a retrospective longitudinal study in COPD patients who were
12 newly admitted to National Clinical Research Center for Respiratory Diseases (NCRCD),
13 a 354-bed, medical and clinical research center in a tertiary hospital in Beijing, China. To
14 comprehensively analyze factors associated with hospital stay, we performed a
15 hypothesis-driven analysis by constructing a conceptual model using directed acyclic
16 graph (DAG). We hypothesized individuals with the aforementioned risk factors were at
17 increased risk for lengthy stay. This was the first clinical epidemiological study to examine
18 factors associated with LOS in Chinese COPD inpatients by the use of conceptual model.
19 It provided some new information about health-care for COPD patients in developing
20 countries and might offer one way to reduce the heavy burden of COPD.
21
22
23
24
25
26
27
28
29
30
31
32
33
34

35 **METHODS**

36
37 We retrospectively analyzed patients consecutively admitted between Jan.1st 2016 to
38 Dec.31th 2017. The eligible patients were Chinese inpatients with primary diagnosis of
39 COPD at initial admission in respiratory units, ≥ 40 years, undergoing pulmonary function
40 testing, and not hospitalized for COPD in preceding one year. Considering the goal to
41 identify patients at high risk of prolonged hospital stay, patients discharged against
42 medical advice were excluded. To ensure that patients were not hospitalized due to COPD
43 in previous one year, data on hospitalizations in 2015 were collected as well. Patients
44 once hospitalized for COPD in 2015 were excluded to remove the influence of preceding
45 COPD admissions within 12 months on the first admission,²⁰ Patients staying longer than
46 30 days were also excluded.
47
48
49
50
51
52
53
54
55
56
57

1
2
3 All diagnoses, including primary and five secondary diagnoses, were determined
4 by International Classification of Diseases, 10th Revision (ICD10) coding system. COPD
5 was defined as J40-J44 in ICD-10 codes. Unique individuals with primary diagnosis of
6 COPD at index admission were identified. To guarantee accuracy of ICD10 coding,
7 diagnoses were ascertained by checking details in medical records.
8
9
10
11
12
13
14
15

16 **Hospital stays**

17
18 LOS was calculated as days by subtracting the admission date from discharge date at the
19 index admission, which was the initial hospital stay. For patients readmitted frequently
20 during study period, their initial hospital stays were included for analyses. If patients were
21 discharged and readmitted on the same day, the readmissions were recorded as the same
22 hospitalization as the initial one. LOS for the same-day discharge and readmission were
23 calculated as the summed days of hospital stay in each consecutive admission.
24
25
26
27
28
29
30
31
32

33 **Direct economic burden**

34
35 As data on days off from work due to COPD disabling effect were unavailable, we only
36 analysed direct health care expenditures during hospitalization for COPD economic
37 burden. Information on total costs and patients' out-of-pocket costs were obtained and
38 converted to U.S. dollars using annual currency exchange rate in 2017 (1 dollar=6.7518
39 yuan).²³
40
41
42
43
44
45
46
47

48 **Potential factors**

49
50 COPD is a complex disease involving airflow obstruction and multisystem diseases,²⁴ We
51 combined secondary diagnoses to characterize COPD's concomitant diseases, including
52 comorbidities and complications according to guidelines²⁵ and researches.^{24,26-28}
53
54 Comorbidities were cardio/cerebro-vascular diseases, diabetes, respiratory infection,
55
56
57
58
59
60

1
2
3 bronchiectasis, gastroesophageal reflux, obstructive sleep apnea syndrome (OSAS), lung
4 cancer, depression or anxiety, and osteoporosis. Complications included respiratory
5 failure, pulmonary heart diseases, hypoxemia, venous thromboembolism (VTE),
6 pneumothorax and pulmonary encephalopathy. As particulates in the air can trigger
7 worsening respiratory symptoms and lead to emergency visiting or hospitalization,²⁹⁻³¹ we
8 collected data on ambient air pollutants at admission. Data on daily concentrations of
9 particulate matter with a diameter of $<2.5 \mu\text{m}$ ($\text{PM}_{2.5}$) and ozone were obtained from the
10 Environment Monitoring Station nearest to the study site. Considering the varying air
11 pollutant concentrations across seasons and potential impact of seasonal changes
12 (temperatures, humidity),³² we also analyzed seasons when the admissions occurred.
13
14 Emergency admission and day of week of admission were analyzed as hospital factors.
15
16 The weekday of admission was dichotomized into Thursday-Sunday and Monday-
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Wednesday.

Patient and public involvement

Patients were not involved in this retrospective study.

Statistics

Data were summarized as number (percentage) for categorical variables and mean \pm SD or median (interquartile ranges [IQR]) for continuous variables as appropriate. To comprehensively analyze potential risk factors for longer LOS and identify important factors, we first developed a conceptual model using DAG. According to the model, baseline covariates were grouped into five blocks: patient demographic characteristics, COPD complications, comorbidities, hospital and environmental factors. Given the overdispersion in distribution of LOS, negative binomial regression was modelled to estimate the effect of potential covariates on hospital stay in each block. Rate ratios (RR,

1
2
3 also known as relative risk) with 95% confidence interval (CI) were reported for the
4 changes in percent of association between covariates and LOS. Then we fitted a final
5 parsimonious model with significant variables obtained in aforementioned models.
6
7 Hospitalization costs among patients with different LOS were compared using Kruskal-
8 Wallis test. All statistical analyses were performed using SAS 9.4 (SAS Institute Inc., Cary,
9 North Carolina, USA) with two-tailed $p < 0.05$.

10
11
12 This study was approved by China-Japan Friendship Hospital Clinical Research
13 Ethics Committee (approval no. 2018-163-K119). Privacy and confidentiality of all patient's
14 information were maintained. Patient informed consent was not required.

25 RESULTS

26 Altogether, 565 new COPD patients were analyzed (Figure S1). The cohort was mostly
27 elderly men residing in local areas. The mean \pm SD age was 69 \pm 11 years. Table 1
28 summarized the general information of eligible patients. Respiratory failure, pulmonary
29 heart diseases, cardiovascular or cerebrovascular diseases, diabetes and respiratory
30 infection were the top co-existing morbidities. Most admissions occurred on Monday-
31 Wednesday. Outpatient departments were the main source for COPD admissions.
32
33 Inpatient numbers were similar across seasons. Median exposure to ambient O₃ and
34 PM_{2.5} were 92 ug/m³ and 52 ug/m³, respectively. LOS was 10 (IQR: 8-14) days and total
35 hospitalization cost was \$2080.7 (1501.6, 2877.17).

47 Conceptual model for LOS

48
49 A conceptual model was developed based on existing knowledge about COPD and its
50 LOS (Table S1).^{17,19,20,29-35} Figure 1 presented the links from individual-level characteristics,
51 health system-related factors, and environmental factors to LOS.
52
53
54
55
56
57
58
59
60

Factors associated with LOS

Based on the conceptual model, we grouped potential factors into five blocks: patient demographic characteristics (age, gender, marital status, residence), lung function and COPD complications, comorbidities, hospital factors (emergency admission, weekday) and environmental factors (season, ozone and PM_{2.5} at admission).

In single model with each block of factors, concomitant VTE (RR 1.38, 95% CI 1.07-1.76) and pulmonary encephalopathy (RR 1.53, 95% CI 1.06-2.20) were associated with an increased risk of longer stay. Lung function was negatively associated with LOS with marginal insignificance. Respiratory infection (RR 1.12, 95% CI: 1.01-1.24), osteoporosis (RR 1.45, 95% CI: 1.07-1.96), and emergence admission (RR 1.08, 95% CI: 1.01-1.16) emerged as significant risk factors for longer LOS. Regarding demographic and environmental factors, no significant associations were observed (Table 2).

In final parsimonious analysis, concomitant VTE, pulmonary encephalopathy, respiratory infection, and osteoporosis remained significant for increased risk in lengthy stay (all $P < 0.05$) (Table 3).

COPD economic burden

Patients having prolonged LOS were supposed to consume greater health resources. We further analyzed the changes in COPD healthcare cost over LOS and observed an upward trend in both total hospitalization cost and patients' out-of-pocket cost (both $P_{\text{trend}} < 0.0001$). Figure 2 depicted the increase in costs among patients with LOS ≤ 8 days, 9-14 days, and > 14 days divided by quantiles.

DISCUSSION

COPD is costly and shortening hospital stay is one way to reduce its high economic burden. In this retrospective study involving nearly 600 COPD patients admitted between 2016

1
2
3 and 2017, we analyzed factors associated with LOS from multiple aspects, aiming to
4 identify high-risk population and risk factors that could be utilized to deliver preventive
5 interventions toward targeted population. COPD complications (VTE, pulmonary
6 encephalopathy) and comorbidities (respiratory infection and osteoporosis) were identified
7 as important factors for prolonged LOS. Direct healthcare cost was in a graded increase
8 with longer LOS.
9
10
11
12
13
14

15 Existing evidence on LOS in COPD patients showed a high heterogeneity and
16 geographical variation.^{17,19,20,36-40} The analysis of COPD audit data across 13 European
17 countries demonstrated an average LOS of 7 days in COPD patients.¹⁷ In a study of COPD
18 comorbidity and LOS in US, mean LOS exceeded one week.⁴⁰ A real-life study in Norway
19 showed a much longer LOS among patients admitted to rehabilitation unit, which were
20 longer than 30 days.³⁹ In our study, the median LOS was 11 days. Risk factors for longer
21 LOS also varied across different studies. Such variance are probably due to disparities in
22 health systems in which patients are managed differently,¹⁷ diverse study population
23 defined by different in/exclusion criteria, and various ways to deal with data, e.g., outcome
24 definitions.^{19,39} In this study, there was a subgroup of patients who were discharged and
25 readmitted immediately on the same day for the same cause of hospitalization. To reflect
26 their real-life experience, we took the same-day discharge and readmission into
27 consideration.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 Co-existing morbidities have been mentioned as predictors of LOS.^{20,21} As shown
44 in our data, VTE predicted longer LOS. It can be provoked by immobilization, heightened
45 systemic inflammation, venous stasis or other factors that place COPD patients at risk of
46 thrombosis.⁴⁰ Patients presenting lower limb swelling, dyspnea or other symptoms usually
47 undergo ultrasound or CT pulmonary angiogram for diagnosis. The additional
48 examinations and antithrombotic therapy can prolong their LOS. Likewise, pulmonary
49 encephalopathy may contribute to the prolonged stay. It occurs when neuronal damage is
50
51
52
53
54
55
56
57

1
2
3 induced by oxygen and CO₂ retention and acidosis⁴¹, resulting in physical impairment and
4 coma, subsequently prolonging hospital stay. Respiratory infections are a common trigger
5 for COPD exacerbation. In our study, it was significantly associated with LOS. The greater
6 bacterial load and inflammation could delay patients' recovery, which, in return, placed
7 patients at greater likelihood of lengthy stay. In an AECOPD study on infectious
8 phenotypes,¹⁴ COPD patients with virus and/or bacteria infection had longer LOS than
9 non-infectious patients. Besides, osteoporosis emerged as another contributor to lengthy
10 stay. In GOLD 2020, osteoporosis is mentioned as a concomitant chronic disease that
11 influences COPD patients' hospitalizations.⁴² Some factors specific to COPD precipitate
12 osteoporosis development, e.g., long-term inhaled corticosteroids use for maintenance
13 therapy^{40,43,44}, and lung function deterioration in disease progress.⁴⁵ Systematic
14 inflammation and oxidative stress through sarcopenia in COPD can lead to bone metabolic
15 abnormalities and COPD-associated osteoporosis⁴⁵, placing COPD patients at an
16 increased risk of fractures and longer stay.⁴⁶ The prolonged LOS in patients with
17 aforementioned concomitant diseases underscore the need for effective management of
18 COPD comorbidities and early prevention.

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37 Additionally, we observed a monotonically increasing trend in both total
38 hospitalization cost and out-of-pocket cost over LOS, indicating longer hospital stay cost
39 more in COPD patients. The domestic and international studies concordantly showed that
40 COPD is a highly expensive disease and hospital-based care cost represents the major
41 cost driver.^{7,12} The proportion varies across regions in China, ranging from 65.9% to
42 77%.^{6,7} In 2016, COPD hospitalization cost was \$3669.33 per patient per admission.¹⁰ In
43 US, hospitalization is responsible for over 70% of total COPD healthcare costs.¹⁹ The
44 direct cost is estimated at \$72 billion annually¹¹ and is projected to be on the rise,^{11,12}
45 imposing substantial economic burden on society and individuals. The issue may be
46 addressed through shortening hospital stay with tailored interventions taken.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

There were several strengths in our study. First, we provided clinical epidemiological data on LOS and its risk factors in newly admitted patients for COPD. Currently, studies on hospital stay are mainly restricted to developed countries.^{14,17-20,22,36,47,48} Our study demonstrated health care for Chinese COPD patients, including a comprehensive risk factor analysis for LOS and an increase of economic burden along with longer stay. Our study, together with the few prior studies in Chinese people,^{14,18} would help fill the gap in knowledge of COPD inpatients' LOS in developing countries. Second, we took the same-day discharge and readmission into consideration when analyzing the collected routinely data in daily clinical practice, which reflected real experiences of hospitalized patients in the real-world clinical setting. The identified risk factors could help determine early interventions to prevent excessive stay, which further reduce economic burden accrued over hospital stay. Hence, the findings are clinically relevant and have clinical implications. In addition, as the analyzed data were from electronic medical records, data collection process was standardized and all data were under scrutiny before entering into electronic system in hospital. Diagnoses of COPD and other diseases were ascertained by reviewing medical records to ensure reliable data. Fourth, the primary data analysis was based on conceptual model by the use of DAG; the findings were theoretical model driven and the visually represented models in DAG made the assumptions about effects of exposures on LOS transparent and explicit.⁴⁹

43
44
45
46
47
48
49
50
51
52
53
54
55
56
57

Hospital stay is a complex issue that is subject to patient, hospital and health system factors. The underlying mechanisms have not been completely disentangled. It merits further investigations to figure out one way to prevent prolonged LOS. The monotonically increasing hospitalization cost with LOS underscores the great importance of shortening hospital stay in reducing COPD economic burden, which may keep rising with the growing and aging population.

1
2
3 There were several limitations. First, the study was performed in NCRCD, one of
4 top hospitals in respiratory field in China. LOS may differ in patients admitted to other
5 health institutes that provide suboptimal care for respiratory disease. To obtain a more
6 comprehensive profile of hospital stay in Chinese COPD patients, a multi-center study
7 involving hospitals across different grades and regions is needed. Second, as information
8 about patients' indirect costs were not available, we used hospitalization costs as a proxy
9 for COPD economic burden. A profound analysis of COPD economic burden should
10 evaluate indirect costs.
11
12
13
14
15
16
17
18
19
20
21

22 **CONCLUSION**

23
24 This study underscores the significance of concomitant morbidities and disease severity
25 in predicting COPD hospital stay. Healthcare cost increased over hospital stay.
26 Identification of high-risk patients for excess stay and delivery of early interventions such
27 as thromboprophylaxis may offer one way to shorten LOS in COPD patients, which would
28 help reduce the economic burden accrued over the stay.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Acknowledgements** we thank hospital's administrative and finance departments for
4
5 their help with data collection.
6

7
8 **Author Contributions** T.Y., J.J.J., C.W. were involved in conceptualization, funding
9
10 acquisition and supervision. F.D., Y.Y.W., Y.L., X.S.L. collected data. F.D., X.X.R., K.H.
11
12 analyzed and interpreted the data. F.D. wrote the draft of manuscript: T.Y., J.J.J., F.D.,
13
14 C.W., K.H., X.X.R., S.W.Q, H.T.N., Y.Y.W., Y.L., M.Y.L., X.S.L. contributed to writing-
15
16 review and approved the final manuscript.
17

18
19 **Funding** This study was supported by National Key R&D Program of China
20
21 (2016YFC0206502), National Key R&D Program of China (2016YFC1303900), CAMS
22
23 Innovation Fund for Medical Sciences (CIFMS) (2018-I2M-1-001), and Science
24
25 Foundation of China-Japan Friendship Hospital for junior researchers (2017-1-QN-3).
26

27
28 **Disclaimer** No conflicts of interest are involved in this manuscript.
29

30
31 **Competing interests** None declared
32

33
34 **Patient consent for publication** Not required
35

36
37 **Ethics approval** We obtained approval from the China-Japan Friendship Hospital Clinical
38
39 Research Ethics Committee (approval no. 2018-163-K119). Privacy and confidentiality of
40
41 all patient's information were maintained. Patient informed consent was not required.
42

43
44 **Data sharing statement** No additional data are available
45

46
47 **Availability of data and material:** Not applicable
48

49
50 **Code availability:** Not applicable
51
52
53
54
55
56
57

REFERENCES

1. Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet (London, England)*. 2019;394(10204):1145-1158.
2. Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. *Lancet (London, England)*. 2018;391(10131):1706-1717.
3. Viniol C, Vogelmeier CF. Exacerbations of COPD. *European respiratory review : an official journal of the European Respiratory Society*. 2018;27(147).
4. Lareau S, Moseson E, Slatore CG. Exacerbation of COPD. *American journal of respiratory and critical care medicine*. 2018;198(11):P21-p22.
5. Donaldson GC, Wedzicha JA. COPD exacerbations .1: Epidemiology. *Thorax*. 2006;61(2):164-168.
6. Chen X, Wang N, Chen Y, Xiao T, Fu C, Xu B. Costs of chronic obstructive pulmonary disease in urban areas of China: a cross-sectional study in four cities. *International journal of chronic obstructive pulmonary disease*. 2016;11:2625-2632.
7. Zhu B, Wang Y, Ming J, Chen W, Zhang L. Disease burden of COPD in China: a systematic review. *International journal of chronic obstructive pulmonary disease*. 2018;13:1353-1364.
8. Fang X, Wang X, Bai C. COPD in China: the burden and importance of proper management. *Chest*. 2011;139(4):920-929.
9. He QY, Zhou X, Xie CM, Liang ZA, Chen P, Wu CG. [Impact of chronic obstructive pulmonary disease on quality of life and economic burden in Chinese urban areas]. *Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases*. 2009;32(4):253-257.

10. Li M, Wang F, Chen R, et al. Factors contributing to hospitalization costs for patients with COPD in China: a retrospective analysis of medical record data. *International journal of chronic obstructive pulmonary disease*. 2018;13:3349-3357.
11. Khakban A, Sin DD, FitzGerald JM, et al. The Projected Epidemic of Chronic Obstructive Pulmonary Disease Hospitalizations over the Next 15 Years. A Population-based Perspective. *American journal of respiratory and critical care medicine*. 2017;195(3):287-291.
12. Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. *ClinicoEconomics and outcomes research : CEOR*. 2013;5:235-245.
13. Ramsey SD, Hobbs FD. Chronic obstructive pulmonary disease, risk factors, and outcome trials: comparisons with cardiovascular disease. *Proceedings of the American Thoracic Society*. 2006;3(7):635-640.
14. Dai MY, Qiao JP, Xu YH, Fei GH. Respiratory infectious phenotypes in acute exacerbation of COPD: an aid to length of stay and COPD Assessment Test. *International journal of chronic obstructive pulmonary disease*. 2015;10:2257-2263.
15. Chen YH, Yao WZ, Cai BQ, et al. Economic analysis in admitted patients with acute exacerbation of chronic obstructive pulmonary disease. *Chinese medical journal*. 2008;121(7):587-591.
16. Ford ES. Hospital discharges, readmissions, and ED visits for COPD or bronchiectasis among US adults: findings from the nationwide inpatient sample 2001-2012 and Nationwide Emergency Department Sample 2006-2011. *Chest*. 2015;147(4):989-998.
17. Ruparel M, Lopez-Campos JL, Castro-Acosta A, Hartl S, Pozo-Rodriguez F, Roberts CM. Understanding variation in length of hospital stay for COPD exacerbation: European COPD audit. *ERJ open research*. 2016;2(1).

- 1
2
3 18. Ko FWS, Chan KP, Ngai J, et al. Blood eosinophil count as a predictor of hospital
4 length of stay in COPD exacerbations. *Respirology (Carlton, Vic)*. 2020;25(3):259-
5 266.
6
7
8
9
10 19. Wang Y, Stavem K, Dahl FA, Humerfelt S, Haugen T. Factors associated with a
11 prolonged length of stay after acute exacerbation of chronic obstructive pulmonary
12 disease (AECOPD). *International journal of chronic obstructive pulmonary disease*.
13 2014;9:99-105.
14
15
16
17 20. Harries TH, Thornton HV, Crichton S, Schofield P, Gilkes A, White PT. Length of
18 stay of COPD hospital admissions between 2006 and 2010: a retrospective
19 longitudinal study. *International journal of chronic obstructive pulmonary disease*.
20 2015;10:603-611.
21
22
23
24
25 21. Roberts CM, Stone RA, Lowe D, Pursey NA, Buckingham RJ. Co-morbidities and
26 90-day outcomes in hospitalized COPD exacerbations. *Copd*. 2011;8(5):354-361.
27
28
29
30
31 22. Limsuwat C, Mankongpaisarnrung C, Dumrongmongcolgul N, Nugent K. Factors
32 influencing the length of hospital stay in patients with acute exacerbations of chronic
33 obstructive pulmonary disease admitted to intensive care units. *Quality*
34 *management in health care*. 2014;23(2):86-93.
35
36
37
38
39 23. National Bureau of Statistics. Available from:
40 http://www.stats.gov.cn/tjsj/zxfb/201802/t20180228_1585631.html. Accessed
41 December 1, 2019.
42
43
44
45 24. Sethi S. Infection as a comorbidity of COPD. *The European respiratory journal*.
46 2010;35(6):1209-1215.
47
48
49
50 25. Celli BR, Decramer M, Wedzicha JA, et al. An official American Thoracic
51 Society/European Respiratory Society statement: research questions in COPD.
52 *European respiratory review : an official journal of the European Respiratory*
53 *Society*. 2015;24(136):159-172.
54
55
56
57
58
59
60

- 1
2
3 26. Cavailles A, Brinchault-Rabin G, Dixmier A, et al. Comorbidities of COPD. *European*
4 *respiratory review : an official journal of the European Respiratory Society.*
5
6 *2013;22(130):454-475.*
7
8
9 27. Garcia-Olmos L, Alberquilla A, Ayala V, et al. Comorbidity in patients with chronic
10 obstructive pulmonary disease in family practice: a cross sectional study. *BMC*
11 *family practice.* 2013;14:11.
12
13
14 28. Guerrero M, Crisafulli E, Liapikou A, et al. Readmission for Acute Exacerbation
15 within 30 Days of Discharge Is Associated with a Subsequent Progressive Increase
16 in Mortality Risk in COPD Patients: A Long-Term Observational Study. *PloS one.*
17 *2016;11(3):e0150737.*
18
19
20 29. Ling SH, van Eeden SF. Particulate matter air pollution exposure: role in the
21 development and exacerbation of chronic obstructive pulmonary disease.
22 *International journal of chronic obstructive pulmonary disease.* 2009;4:233-243.
23
24
25 30. Li J, Sun S, Tang R, et al. Major air pollutants and risk of COPD exacerbations: a
26 systematic review and meta-analysis. *International journal of chronic obstructive*
27 *pulmonary disease.* 2016;11:3079-3091.
28
29
30 31. Anderson JO, Thundiyil JG, Stolbach A. Clearing the air: a review of the effects of
31 particulate matter air pollution on human health. *Journal of medical toxicology :*
32 *official journal of the American College of Medical Toxicology.* 2012;8(2):166-175.
33
34
35 32. Donaldson GC, Wedzicha JA. The causes and consequences of seasonal variation
36 in COPD exacerbations. *International journal of chronic obstructive pulmonary*
37 *disease.* 2014;9:1101-1110.
38
39
40 33. Hillas G, Perlikos F, Tsiligianni I, Tzanakis N. Managing comorbidities in COPD.
41 *International journal of chronic obstructive pulmonary disease.* 2015;10:95-109.
42
43
44 34. Eccles R. An explanation for the seasonality of acute upper respiratory tract viral
45 infections. *Acta oto-laryngologica.* 2002;122(2):183-191.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 35. Parappil A, Depczynski B, Collett P, Marks GB. Effect of comorbid diabetes on
4 length of stay and risk of death in patients admitted with acute exacerbations of
5 COPD. *Respirology (Carlton, Vic)*. 2010;15(6):918-922.
6
7
8
9 36. Agboado G, Peters J, Donkin L. Factors influencing the length of hospital stay
10 among patients resident in Blackpool admitted with COPD: a cross-sectional study.
11 *BMJ open*. 2012;2(5).
12
13
14
15 37. Holland M, Alkhalil M, Chandromouli S, Janjua A, Babores M. Eosinopenia as a
16 marker of mortality and length of stay in patients admitted with exacerbations of
17 chronic obstructive pulmonary disease. *Respirology (Carlton, Vic)*. 2010;15(1):165-
18 167.
19
20
21
22
23 38. Ingadottir AR, Beck AM, Baldwin C, et al. Association of energy and protein intakes
24 with length of stay, readmission and mortality in hospitalised patients with chronic
25 obstructive pulmonary disease. *The British journal of nutrition*. 2018;119(5):543-551.
26
27
28
29 39. Vitacca M, Marino S, Comini L, Fezzardi L, Paneroni M. Bacterial Colonization in
30 COPD Patients Admitted to a Rehabilitation Respiratory Unit and Impact on Length
31 of Stay: A Real-Life Study. *Copd*. 2018;15(6):581-587.
32
33
34
35 40. Inabnit LS, Blanchette C, Ruban C. Comorbidities and length of stay in chronic
36 obstructive pulmonary disease patients. *Copd*. 2018;15(4):355-360.
37
38
39 41. J Han, F Zeng, S Cheng, Z Gong, Zhou Y. The Role of Neurous Autophagy in
40 Pulmonary Encephalopathy and Signaling Pathways. *West Indian Medical Journal*.
41 2015.
42
43
44
45 42. Global strategy for the diagnosis, management and prevention of chronic
46 obstructive pulmonary disease 2020 report [EB/OL] (2019-11-05) [Accessed April
47 12, 2020]. <https://goldcopd.org/gold-reports/>.
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 43. Waljee AK, Rogers MA, Lin P, et al. Short term use of oral corticosteroids and
4 related harms among adults in the United States: population based cohort study.
5
6 *BMJ (Clinical research ed)*. 2017;357:j1415.
7
8
9
10 44. Jorgensen NR, Schwarz P, Holme I, Henriksen BM, Petersen LJ, Backer V. The
11 prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a
12 cross sectional study. *Respiratory medicine*. 2007;101(1):177-185.
13
14
15 45. Okazaki R, Watanabe R, Inoue D. Osteoporosis Associated with Chronic
16 Obstructive Pulmonary Disease. *J Bone Metab*. 2016;23(3):111-120.
17
18
19 46. Papaioannou A, Adachi JD, Parkinson W, Stephenson G, Bedard M. Lengthy
20 hospitalization associated with vertebral fractures despite control for comorbid
21 conditions. *Osteoporos Int*. 2001;12(10):870-874.
22
23
24
25 47. Rinne ST, Wong ES, Hebert PL, et al. Weekend Discharges and Length of Stay
26 Among Veterans Admitted for Chronic Obstructive Pulmonary Disease. *Medical*
27 *care*. 2015;53(9):753-757.
28
29
30
31 48. Quintana JM, Unzurrunzaga A, Garcia-Gutierrez S, et al. Predictors of Hospital
32 Length of Stay in Patients with Exacerbations of COPD: A Cohort Study. *Journal of*
33 *general internal medicine*. 2015;30(6):824-831.
34
35
36
37
38 49. Lederer DJ, Bell SC, Branson RD, et al. Control of Confounding and Reporting of
39 Results in Causal Inference Studies. Guidance for Authors from Editors of
40 Respiratory, Sleep, and Critical Care Journals. *Annals of the American Thoracic*
41 *Society*. 2019;16(1):22-28.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Characteristics of patients hospitalized for COPD

	Study patients N=565	Values ^a
Demographic	Age, years	69±11
characteristics	Men	392 (69.4)
	Married	544 (96.3)
	Local resident	361 (63.9)
Lung function and complications ^b	Pre-FEV1	1.16 (0.84, 1.73)
	Respiratory failure	63 (11.4)
	Pulmonary heart diseases	59 (10.7)
	Hypoxemia	10 (1.8)
	VTE	9 (1.6)
	Pneumothorax	2 (0.4)
	Pulmonary encephalopathy	4 (0.7)
Comorbidities ^b	Cardio/Cerebrovascular Diseases	340 (61.7)
	Diabetes	102 (18.5)
	Respiratory infection	67 (12.2)
	Bronchiectasis	47 (8.5)
	Reflux esophagitis	38 (6.9)
	OSAS	18 (3.3)
	Lung cancer	5 (0.9)
	Anxiety depression	12 (2.2)
	Osteoporosis	6 (1.1)
Admission	Obesity	56 (9.9)
	Admitted on Thursday-Sunday	252 (44.6)
	Admitted from emergency	173 (30.7)

Study patients N=565		Values ^a
Seasons at admission	March-May	164 (29.0)
	June-August	145 (25.7)
	Sep.-Nov.	94 (16.6)
	Dec.-Feb.	162 (28.7)
Air pollution at admission	O ₃ , ug/m ³	92 (63, 150)
	PM _{2.5} , ug/m ³	52 (25, 88)
Hospital stay and healthcare cost	Length of stay, days	10 (8, 14)
	Direct cost of hospitalization, \$	2080.7 (1501.6, 2877.17)

^a Data were represented as mean ± SD or median (Interquartile) for continuous variables where appropriate and n (%) for categorical variables.

^b Fourteen patients' complications and comorbidities were missing due to their unavailable data on secondary diagnoses.

Table 2. Single model analysis for factors associated with hospital stay at index admission based on DAG

Block	Variable	RR 95%CI	P value
Demographic characteristics	Age, per 5 years	1.01 (0.998-1.03)	0.094
	Male	1.05 (0.97-1.13)	0.237
	Married	0.88 (0.74-1.05)	0.158
	Local residents	1.04 (0.96-1.12)	0.334
Lung function and complications	FEV1	0.97 (0.95-1.00)	0.055
	Respiratory failure	1.05 (0.94-1.18)	0.396
	Pulmonary heart diseases	1.03 (0.92-1.16)	0.624
	Hypoxemia	0.96 (0.74-1.24)	0.757
	VTE	1.38 (1.07-1.76)	0.012*
	Pneumothorax	1.63 (0.98-2.70)	0.057
	Pulmonary encephalopathy	1.53 (1.06-2.20)	0.023*
	COPD	Cardio/Cerebrovascular Diseases	1.05 (0.98-1.13)
comorbidities	Diabetes	0.98 (0.90-1.07)	0.648
	Respiratory infection	1.12 (1.01-1.24)	0.035*
	Bronchiectasis	1.00 (0.88-1.13)	0.967
	Reflux esophagitis	1.00 (0.88-1.15)	0.959
	OSAS	1.17 (0.97-1.42)	0.094
	Lung cancer	1.09 (0.77-1.57)	0.620
	Anxiety depression	0.89 (0.69-1.13)	0.324
	Osteoporosis	1.45 (1.07-1.96)	0.018*
Hospital factors	Obesity	0.97 (0.86-1.08)	0.559
	Admitted on Thursday-Sunday	1.04 (0.97-1.11)	0.319

Block	Variable	RR 95%CI	P value
	Admitted from emergency	1.08 (1.01-1.16)	0.033*
Environmental factors	Season at admission, Mar.-May	1.01 (0.91-1.12)	0.850
	Season at admission, Jun.-Aug.	1.08 (0.96-1.22)	0.176
	Season at admission, Sep.-Nov.	0.98 (0.88-1.09)	0.752
	O3, per 10 ug/m ³	1.00 (0.995-1.01)	0.573
	PM2.5, per 10 ug/m ³	1.00 (0.998-1.01)	0.217

^a $P < 0.05$

Table 3. Parsimonious analysis for factors associated with hospital stay at index admission

Variable	RR 95%CI	P value
Age, per 5 years	1.01 (0.997-1.03)	0.126
Pre-FEV1	0.97 (0.95-1.00)	0.055
VTE	1.40 (1.09-1.78)	0.007*
Pulmonary encephalopathy	1.53 (1.07-2.18)	0.020*
Respiratory infection	1.11 (1.01-1.23)	0.040*
Osteoporosis	1.42 (1.05-1.91)	0.021*
Emergency admission	1.06 (0.98-1.14)	0.147

^a $P < 0.05$

1
2
3 **Figure 1. Conceptual model using directed acyclic graph (DAG) for factors**
4
5 **associated with hospital stay**
6

7 Based on current knowledge on COPD risk factors, we developed a conceptual model
8 using DAG. Potential covariates at baseline were grouped into five blocks: patient
9 demographic characteristics (age, gender, marital status, residence), COPD
10 complications, comorbidities, hospital factors (emergency admission, weekday of
11 admission) and environmental factors (season, ozone and PM_{2.5} at admission).
12
13
14
15
16
17
18
19

20 **Figure 2. COPD costs during hospitalization**
21

22 During hospitalization, total cost and the out-of-pocket cost were compared among
23 patients with LOS ≤8 days, 9-14 days, and >14 days according to quartiles of LOS. The
24 costs increased with longer LOS ($P_{\text{trend}} < 0.0001$ for both total cost and the out-of-pocket
25 cost).
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Conceptual model using directed acyclic graph (DAG) for factors associated with hospital stay. Based on current knowledge on COPD risk factors, we developed a conceptual model using DAG. Potential covariates at baseline were grouped into five blocks: patient demographic characteristics (age, gender, marital status, residence), COPD complications, comorbidities, hospital factors (emergency admission, weekday of admission) and environmental factors (season, ozone and PM2.5 at admission).

122x104mm (600 x 600 DPI)




Figure 2. COPD costs during hospitalization

During hospitalization, total cost and the out-of-pocket cost were compared among patients with LOS ≤ 8 days, 9-14 days, and > 14 days according to quartiles of LOS. The costs increased with longer LOS (Ptrend < 0.0001 for both total cost and the out-of-pocket cost).

228x152mm (300 x 300 DPI)

SUPPLEMENTARY INFORMATION

Factors Associated with Inpatient Length of Stay among Hospitalized Patients with Chronic Obstructive Pulmonary Disease, China, 2016-2017: a retrospective study

Fen Dong¹, Ke Huang², Xiaoxia Ren², Shiwei Qumu², Hongtao Niu², Yanyan Wang³,

Yong Li², Minya Lu⁴, Xinshan Lin^{2,5}, Ting Yang^{2*}, Jianjun Jiao^{6*}, Chen Wang^{2,7}

***Co-corresponding authors:** Ting Yang and Jianjun Jiao contributed equally to this paper as co-corresponding authors.

Affiliations:

¹Institute of Clinical Medical Sciences, China–Japan Friendship Hospital, Beijing, China;

²Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Chinese Academy of Medical Science, Beijing, China;

³Department of Medical Records, China–Japan Friendship Hospital, Beijing, China;

⁴Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China;


⁵Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China;

⁶Department of Medical Administration, China–Japan Friendship Hospital, Beijing, China;

⁷Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

1
2
3
4 **Supplementary** Figure S1- Flow chart of data cleaning process

5 **Supplementary** Table S1- Observational studies on LOS and risk factors in patients
6 admitted for COPD
7
8
9



43 **Figure S1- Flow chart of data cleaning process**

Table S1. Observational studies on LOS and risk factors in patients admitted for COPD ^a

Countries/regions	Years for LOS	Study patients	LOS	Risk factors for longer LOS
Thirteen European counties ¹	Oct.-Dec.2010; Jan.-Feb. 2011	Exacerbated COPD patients in Europe	Median (IQR): 7 (4-11) days	Clinical severity, treatment
UK ²⁻⁵	2006-2010	COPD patients registered with London general practitioners aged ≥45 years	Mean: 8.2 days in 2006 and 7 days in 2010	Age, hospital and community factors
	Apr.1st, 2005- Mar.31st, 2010	COPD patients aged ≥40 years in Blackpool, UK	Median: 6 days Mean: 9.8 days	Age, deprivation, Charlson index, specialty of admission, and cause of exacerbations
	Mar. 2007- Apr. 2008	65 AECOPD patients	Median: 5 (1-27) in normal eosinophils and 8 (2-61) in eosinopenia	Eosinopenia
	Mar. 2015-Mar. 2016	99 COPD patients admitted to department of pulmonary medicine at Landspítali National University hospital	9 days	No clear association between energy or protein intake and LOS
Norway ⁶	March 2006-December 2008	Patients discharged after COPD at Oslo University hospital in Norway	Median: 6 (3.5-11) days	Admission between Thursday and Saturday, heart failure, diabetes, stroke, high arterial PCO ₂ , and low serum albumin level were associated with LOS>11 days. ^b

Countries/regions	Years for LOS	Study patients	LOS	Risk factors for longer LOS
Italy ⁷	2010	269 COPD patients in a respiratory rehabilitation unit in Italy	Mean ±SD: 31±17 days	Comorbidity, age, invasive procedure, disability, admission provenance predicted longer stay (≥ 30 days) ^b
Portugal ⁸	Jan-Jun., 2016	242 diabetic patients with AECOPD or community acquired pneumonia	Median: 10 days (min-max, 1-66)	LOS was positively correlated with glycemic variability
Spain ⁹	Jun. 2008-Sep. 2010	AECOPD patients visiting emergency department in Spain	-	Baseline dyspnea, physical activity level, and hospital variability
US ^{10,11}	Jan. 1st, -Dec. 31st, 2016	3399 COPD patients with LOS ≤60 days in Premier healthcare database	Mean ± SD: 11.64±9.40 days	Comorbidity (congestive heart failure, fluid and electrolyte disorders, renal failure) were associated with longer stay
	Oct. 1st, 2008- Sep. 30th, 2010	25301 COPD patients admitted to veteran affairs health care system	Mean ± SD: 4.2±2.7 days for weekend discharged patients, 5.4±4.9 days for weekday discharged patients	Fewer weekend discharges was associated with longer stay.
Australia ¹²	2007	172 AECOPD patients	7.8 days in patients with diabetes, 6.5 days in patients without diabetes	Patients with diabetes had increased LOS, but differences were not statistically significant after adjustment for covariates.
China ^{13,14}	Mar. 2013-Aug.2016	346 AECOPD patients in a tertiary hospital in Hongkong, China	Median (IQR): 5 (7) days	An eosinophil value of <0.144 × 10 ⁹ /L on admission or <2% was associated with

Countries/regions	Years for LOS	Study patients	LOS	Risk factors for longer LOS
				longer hospital LOS (≥ 5 days) for AECOPD ^b
	January-June, 2014	81 exacerbated COPD patients in a hospital in Anhui, China	Mean \pm SD: 9.6 \pm 4.1 days	Respiratory infection was associated with LOS

^a we conducted a literature review by searching literatures in the following database: Medline, Embase, Pubmed and Web of Science. We searched observational studies that focused on risk factors of longer hospital stay at index admission in COPD inpatients. Terms used in search were: "Chronic obstructive pulmonary disease", "COPD", "hospitalization", "length of stay", "LOS", and "hospital stay". Published years ranged from 2000 to 2019. Study types included prospective study, retrospective study, cohort analysis or observational study. We also searched the references in retrieved papers for supplement studies that may be missed during the search

^b In risk factor analysis, LOS was categorized into a binary variable.^{6,7,13}

AECOPD=acute exacerbation of COPD; UK=United Kingdom; US=United States

References

1. Ruparel M, Lopez-Campos JL, Castro-Acosta A, Hartl S, Pozo-Rodriguez F, Roberts CM. Understanding variation in length of hospital stay for COPD exacerbation: European COPD audit. *ERJ open research*. 2016;2(1).
2. Harries TH, Thornton HV, Crichton S, Schofield P, Gilkes A, White PT. Length of stay of COPD hospital admissions between 2006 and 2010: a retrospective longitudinal study. *International journal of chronic obstructive pulmonary disease*. 2015;10:603-611.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

3. Agboado G, Peters J, Donkin L. Factors influencing the length of hospital stay among patients resident in Blackpool admitted with COPD: a cross-sectional study. *BMJ open*. 2012;2(5).
4. Holland M, Alkhalil M, Chandromouli S, Janjua A, Babores M. Eosinopenia as a marker of mortality and length of stay in patients admitted with exacerbations of chronic obstructive pulmonary disease. *Respirology (Carlton, Vic)*. 2010;15(1):165-167.
5. Ingadottir AR, Beck AM, Baldwin C, et al. Association of energy and protein intakes with length of stay, readmission and mortality in hospitalised patients with chronic obstructive pulmonary disease. *The British journal of nutrition*. 2018;119(5):543-551.
6. Wang Y, Stavem K, Dahl FA, Humerfelt S, Haugen T. Factors associated with a prolonged length of stay after acute exacerbation of chronic obstructive pulmonary disease (AECOPD). *International journal of chronic obstructive pulmonary disease*. 2014;9:99-105.
7. Vitacca M, Marino S, Comini L, Fezzardi L, Paneroni M. Bacterial Colonization in COPD Patients Admitted to a Rehabilitation Respiratory Unit and Impact on Length of Stay: A Real-Life Study. *Copd*. 2018;15(6):581-587.
8. Ferreira L, Moniz AC, Carneiro AS, et al. The impact of glycemic variability on length of stay and mortality in diabetic patients admitted with community-acquired pneumonia or chronic obstructive pulmonary disease. *Diabetes & metabolic syndrome*. 2019;13(1):149-153.
9. Quintana JM, Unzurrunzaga A, Garcia-Gutierrez S, et al. Predictors of Hospital Length of Stay in Patients with Exacerbations of COPD: A Cohort Study. *Journal of general internal medicine*. 2015;30(6):824-831.
10. Inabnit LS, Blanchette C, Ruban C. Comorbidities and length of stay in chronic obstructive pulmonary disease patients. *Copd*. 2018;15(4):355-360.
11. Rinne ST, Wong ES, Hebert PL, et al. Weekend Discharges and Length of Stay Among Veterans Admitted for Chronic Obstructive Pulmonary Disease. *Medical care*. 2015;53(9):753-757.
12. Parappil A, Depczynski B, Collett P, Marks GB. Effect of comorbid diabetes on length of stay and risk of death in patients admitted with acute exacerbations of COPD. *Respirology (Carlton, Vic)*. 2010;15(6):918-922.
13. Ko FWS, Chan KP, Ngai J, et al. Blood eosinophil count as a predictor of hospital length of stay in COPD exacerbations. *Respirology (Carlton, Vic)*. 2020;25(3):259-266.

- 1
2
3
4
5 14. Dai MY, Qiao JP, Xu YH, Fei GH. Respiratory infectious phenotypes in acute exacerbation of COPD: an aid to length of stay and COPD
6 Assessment Test. *International journal of chronic obstructive pulmonary disease*. 2015;10:2257-2263.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

For peer review only

Reporting checklist for cohort study.

Based on the STROBE cohort guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the STROBE cohort reporting guidelines, and cite them as:

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

	Reporting Item	Page Number
Title and abstract		
Title	#1a Indicate the study's design with a commonly used term in the title or the abstract	1
Abstract	#1b Provide in the abstract an informative and	3

1 balanced summary of what was done and what
2
3 was found
4

5 Introduction

6
7
8
9 Background / [#2](#) Explain the scientific background and rationale 5
10 rationale for the investigation being reported
11
12

13
14 Objectives [#3](#) State specific objectives, including any 6
15 prespecified hypotheses
16
17

18 Methods

19
20
21
22
23 Study design [#4](#) Present key elements of study design early in 6
24 the paper
25
26

27
28 Setting [#5](#) Describe the setting, locations, and relevant 6
29 dates, including periods of recruitment,
30 exposure, follow-up, and data collection
31
32
33

34
35
36 Eligibility criteria [#6a](#) Give the eligibility criteria, and the sources and 6
37 methods of selection of participants. Describe
38 methods of follow-up.
39
40
41
42

43 Eligibility criteria [#6b](#) For matched studies, give matching criteria and n/a
44 number of exposed and unexposed
45
46
47

48
49 Variables [#7](#) Clearly define all outcomes, exposures, 7-8
50 predictors, potential confounders, and effect
51 modifiers. Give diagnostic criteria, if applicable
52
53
54
55

56 Data sources / [#8](#) For each variable of interest give sources of 6-8
57
58
59

1	measurement		data and details of methods of assessment	
2			(measurement). Describe comparability of	
3			assessment methods if there is more than one	
4			group. Give information separately for for	
5			exposed and unexposed groups if applicable.	
6				
7				
8				
9				
10				
11				
12	Bias	#9	Describe any efforts to address potential	6
13			sources of bias	
14				
15				
16				
17				
18	Study size	#10	Explain how the study size was arrived at	n/a. In this
19				retrospectively
20				cohort,
21				patients were
22				consecutively
23				admitted
24				
25				
26				
27				
28				
29				
30				
31				
32	Quantitative	#11	Explain how quantitative variables were	7-9
33	variables		handled in the analyses. If applicable, describe	
34			which groupings were chosen, and why	
35				
36				
37				
38				
39				
40	Statistical	#12a	Describe all statistical methods, including those	8-9
41	methods		used to control for confounding	
42				
43				
44				
45	Statistical	#12b	Describe any methods used to examine	n/a. In this
46	methods		subgroups and interactions	study, we
47				studied
48				potential
49				factors related
50				to length of
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

stay in COPD

patients

Statistical [#12c](#) Explain how missing data were addressed 23 Table 1

methods

Statistical [#12d](#) If applicable, explain how loss to follow-up was

methods addressed

Statistical [#12e](#) Describe any sensitivity analyses

methods

Results

Participants [#13a](#) Report numbers of individuals at each stage of 9 Figure S1

study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed. Give information separately for for exposed and unexposed groups if applicable.

Participants [#13b](#) Give reasons for non-participation at each 9 Figure S1

stage

Participants [#13c](#) Consider use of a flow diagram 9 Figure S1

Descriptive data [#14a](#) Give characteristics of study participants (eg 9, 23 Table 1

demographic, clinical, social) and information on exposures and potential confounders. Give information separately for exposed and unexposed groups if applicable.

1	Descriptive data	#14b	Indicate number of participants with missing	23 Table 1
2				
3			data for each variable of interest	
4				
5				
6	Descriptive data	#14c	Summarise follow-up time (eg, average and	7, hospital
7			total amount)	stay at the
8				initial
9				admission
10				was the
11				follow-up time
12				
13				
14				
15				
16				
17				
18				
19				
20				
21	Outcome data	#15	Report numbers of outcome events or	9, 23 Table 1
22			summary measures over time. Give information	
23			separately for exposed and unexposed groups	
24			if applicable.	
25				
26				
27				
28				
29				
30				
31	Main results	#16a	Give unadjusted estimates and, if applicable,	10, 24-26
32			confounder-adjusted estimates and their	Table 2-3
33			precision (eg, 95% confidence interval). Make	
34			clear which confounders were adjusted for and	
35			why they were included	
36				
37				
38				
39				
40				
41				
42				
43	Main results	#16b	Report category boundaries when continuous	10 Figure 2
44			variables were categorized	
45				
46				
47				
48	Main results	#16c	If relevant, consider translating estimates of	n/a. Relative
49			relative risk into absolute risk for a meaningful	risk was the
50			time period	main indicator
51				for length of
52				stay in this
53				
54				
55				
56				
57				
58				
59				
60				

1			paper
2			
3			
4	Other analyses	#17	Report other analyses done—e.g., analyses of
5			n/a. This
6			study focused
7			on the
8			potential
9			factors
10			associated
11			with
12			prolonged
13			hospital stay
14			in COPD
15			patients
16			
17			
18			
19			
20			
21			
22			
23			
24			
25			
26			
27			
28			
29	Discussion		
30			
31			
32	Key results	#18	Summarise key results with reference to study
33			10-11
34			objectives
35			
36			
37			
38	Limitations	#19	Discuss limitations of the study, taking into
39			14
40			account sources of potential bias or
41			imprecision. Discuss both direction and
42			magnitude of any potential bias.
43			
44			
45			
46			
47			
48	Interpretation	#20	Give a cautious overall interpretation
49			14
50			considering objectives, limitations, multiplicity
51			of analyses, results from similar studies, and
52			other relevant evidence.
53			
54			
55			
56			
57			
58	Generalisability	#21	Discuss the generalisability (external validity) of
59			14
60			

the study results

Other

Information

Funding

[#22](#)

Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

15

None The STROBE checklist is distributed under the terms of the Creative Commons Attribution License CC-BY. This checklist can be completed online using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

BMJ Open

Factors Associated with Inpatient Length of Stay among Hospitalized Patients with Chronic Obstructive Pulmonary Disease, China, 2016-2017: a retrospective study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-040560.R1
Article Type:	Original research
Date Submitted by the Author:	10-Dec-2020
Complete List of Authors:	<p>Dong, Fen; Institute of Clinical Medical Sciences, China-Japan Friendship Hospital,</p> <p>Huang, Ke; China-Japan Friendship Hospital, Department of Pulmonary and Critical Care Medicine; National Clinical Research Center for Respiratory Diseases</p> <p>Ren, Xiaoxia; China-Japan Friendship Hospital, Department of Pulmonary and Critical Care Medicine; National Clinical Research Center for Respiratory Diseases</p> <p>Qumu, Shiwei; China-Japan Friendship Hospital, Department of Pulmonary and Critical Care Medicine; National Clinical Research Center for Respiratory Diseases</p> <p>Niu, Hongtao; China-Japan Friendship Hospital, Department of Pulmonary and Critical Care Medicine; National Clinical Research Center for Respiratory Diseases</p> <p>Wang, Yanyan; China-Japan Friendship Hospital, Department of Medical Records</p> <p>Li, Yong; China-Japan Friendship Hospital, Department of Pulmonary and Critical Care Medicine; National Clinical Research Center for Respiratory Diseases</p> <p>Lu, Minya; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Department of Clinical Laboratory</p> <p>Lin, Xinshan; China-Japan Friendship Hospital, Department of Pulmonary and Critical Care Medicine; Chinese Academy of Medical Sciences & Peking Union Medical College, Graduate School of Peking Union Medical College</p> <p>Yang, Ting; China-Japan Friendship Hospital, Department of Pulmonary and Critical Care Medicine; National Clinical Research Center for Respiratory Diseases</p> <p>Jiao, Jianjun; China-Japan Friendship Hospital, Department of Medical Administration</p> <p>Wang, Chen; China-Japan Friendship Hospital, Department of Pulmonary and Critical Care Medicine; Chinese Academy of Medical Sciences & Peking Union Medical College</p>
Primary Subject Heading:	Respiratory medicine
Secondary Subject Heading:	Epidemiology, Respiratory medicine
Keywords:	Chronic airways disease < THORACIC MEDICINE, Epidemiology <

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	THORACIC MEDICINE, Risk management < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Factors Associated with Inpatient Length of Stay among**
4
5
6 **Hospitalized Patients with Chronic Obstructive Pulmonary**
7
8 **Disease, China, 2016-2017: a retrospective study**
9

10
11 Fen Dong¹, Ke Huang², Xiaoxia Ren², Shiwei Qumu², Hongtao Niu², Yanyan Wang³, Yong
12
13 Li², Minya Lu⁴, Xinshan Lin^{2,5}, Ting Yang^{2*}, Jianjun Jiao^{6*}, Chen Wang^{2,7}
14
15

16
17 ***Co-corresponding authors:** Ting Yang and Jianjun Jiao contributed equally to this
18
19 paper as co-corresponding authors.
20
21

22
23 **Affiliations:**
24

25
26 ¹Institute of Clinical Medical Sciences, China–Japan Friendship Hospital, Beijing, China;
27

28 ²Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital;
29
30 National Clinical Research Center for Respiratory Diseases; Institute of Respiratory
31
32 Medicine, Chinese Academy of Medical Science, Beijing, China;
33

34 ³Department of Medical Records, China–Japan Friendship Hospital, Beijing, China;
35

36 ⁴Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese
37
38 Academy of Medical Sciences, Beijing, China;
39

40 ⁵Graduate School of Peking Union Medical College, Chinese Academy of Medical
41
42 Sciences & Peking Union Medical College, Beijing, China;
43

44 ⁶Department of Medical Administration, China–Japan Friendship Hospital, Beijing,
45
46 China;
47

48
49 ⁷Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
50
51

52
53 **Correspondence:** Ting Yang
54
55
56
57

1
2
3 Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital;
4
5 National Clinical Research Center for Respiratory Diseases; Institute of Respiratory
6
7 Medicine, Chinese Academy of Medical Science. No 2, East Yinghua Road, Chaoyang
8
9 District, Beijing, China
10

11
12 Tel : +010 8420 6273

13
14 Email : dryangting@qq.com
15

16
17
18 **Word count** : 2772, excluding the title page, abstract, tables, acknowledgements,
19
20 contributions and references.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives: To identify factors associated with length of stay (LOS) in Chronic obstructive pulmonary disease (COPD) hospitalized patients, which may help shorten LOS and reduce economic burden accrued over hospital stay.

Design: A retrospective cohort study

Setting: This study was performed in a tertiary hospital in China.

Participants: COPD patients who were aged ≥ 40 years and newly admitted between 2016 and 2017.

Primary and secondary outcome measures: LOS at initial admission was the primary outcome and health expenditures were the secondary outcome. To identify factors associated with LOS, we collected information at index hospitalization and constructed a conceptual model using directed acyclic graph. Potential factors were classified into five groups: demographic information, disease severity, comorbidities, hospital admission, and environmental factors. Negative binomial regression model was fitted for each block of factors and a parsimonious analysis was performed.

Results: Totally, we analyzed 565 COPD patients. The mean age was 69 ± 11 years old and 69.4% were male. The median LOS was 10 (IQR 8-14) days. LOS was significantly longer in patients with venous thromboembolism (VTE) (16 vs 10 days, $p=0.0002$) or with osteoporosis (15 vs 10 days, $p=0.0228$). VTE (RR 1.38, 95% CI 1.07-1.76), hypoxic-hypercarbic encephalopathy (RR 1.53, 95%CI 1.06-2.20), respiratory infection (RR 1.12, 95%CI 1.01-1.24), osteoporosis (RR 1.45, 95%CI 1.07-1.96), and emergence admission (RR 1.08, 95%CI 1.01-1.16) were associated with longer LOS. In parsimonious analysis, all these factors remained significant except emergency admission, highlighting the important role of concomitant morbidities in patients' hospital stay. Total hospitalization cost and patients' out-of-pocket cost increased monotonically with LOS (both $p_{\text{trend}} < 0.0001$).

1
2
3 **Conclusion:** Patients' concomitant morbidities predicted excessive LOS in COPD
4 patients. Healthcare cost increased over the length of stay. Quality improvement initiatives
5 may need to identify patients at high risk for lengthy stay and implement early interventions
6 to reduce COPD economic burden.
7
8
9
10

11
12
13 **Keywords:** Pulmonary disease, Chronic obstructive; Length of Stay; Risk Factors; DAG
14
15

16 **Article Summary**

17 **Strengths and limitations of this study**

- 18 ● LOS and economic burden were analyzed in newly admitted COPD patients in
19 developing countries.
- 20 ● The primary data analysis was based on conceptual model and theoretical model
21 driven
- 22 ● Real experiences of hospitalized patients in the real-world clinical setting were
23 analyzed
- 24 ● Analysis in this single center study may not reflect the comprehensive profile of LOS
25 in Chinese patients.
- 26 ● Indirect hospitalization costs were not analyzed due to unavailability of data on
27 patients' indirect costs.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is a burdensome chronic respiratory disease. It's estimated to cause 2.6% Disability-Adjusted Life Years (DALYs) globally and ranked as the third top cause of DALYs in China.¹ The prevalence of COPD in Chinese adults is 8.6%, with approximately 100 million COPD patients.² People aged over 40 years are particularly at high risk due to its onset in later life. During COPD progress, acute worsening respiratory symptoms can be easily triggered,^{3,4} leading to hospitalizations and increased use of health service.⁵ Spending on hospital-based care constitute the major healthcare cost in COPD patients, accounting for 65.9%-77% of medical costs in China.^{6,7} The direct medical cost of COPD was estimated at \$1732.24 per patient annually in 2006^{8,9} and hospitalization cost per admission increased to \$3669.33 in 2016.¹⁰ COPD is also a costly disease in developed countries. In US, it consumes \$72 billion in direct healthcare cost each year¹¹ and the tremendous cost is projected to be on the rise.^{11,12} Given the large prevalent population and substantial economic burden, interventions targeted to COPD hospitalization are needed. Hospital stay is an important outcome for health care systems¹³ and indicates the acute impact of exacerbation on patients.¹⁴ Length of stay (LOS) correlates with hospitalization cost.¹⁵ Shortening LOS might be one way to slow down the escalating healthcare cost.

Owing to disparities in healthcare systems or service use, there exists a high heterogeneity of LOS across countries.^{12,16,17} In China, some patients stay longer under certain circumstances, eg, discharged and readmitted on the same day due to complicated conditions, prolonging their actual stay for the same hospitalization. Two prior studies in Chinese COPD patients demonstrated that respiratory coinfection and eosinopenia were associated with longer stay.^{14,18} However, these studies focused more on single exposure-outcome relationship between one risk factor and LOS. The lengthy stay is multifactorial and a diversity of factors can contribute to prolonged LOS, such as poor patients' health

1
2
3 status, complicated disease conditions, and organization operation et al.^{17,19-22} Some of
4 these factors are related to health system and some are patient-level factors. To effectively
5 reduce LOS and COPD disease burden, it's of paramount importance to identify important
6 factors associated with LOS.
7
8
9
10

11 Thus, we conducted a retrospective longitudinal study to analyze factors
12 associated with hospital stay. Study population were COPD patients who were newly
13 admitted to National Clinical Research Center for Respiratory Diseases (NCRCD), a
14 354-bed, medical and clinical research center in a tertiary hospital in Beijing, China.
15
16
17
18
19
20
21

22 **METHODS**

23
24 We retrospectively analyzed patients consecutively admitted between Jan.1st 2016 to
25 Dec.31st 2017. The eligible patients were Chinese inpatients with primary diagnosis of
26 COPD at initial admission in respiratory units, who were aged ≥ 40 years and had
27 pulmonary function testing. Considering the aim to identify patients at high risk of
28 prolonged hospital stay, patients discharged against medical advice were excluded.
29 Patients who had been hospitalized for COPD in 2015 were also excluded to remove the
30 influence of COPD admissions within prior 12 months on the first admission during the
31 study period.²⁰ Patients with LOS longer than 30 days at the first admission were excluded
32 as well.
33
34
35
36
37
38
39
40
41
42

43 All diagnoses, including primary and five secondary diagnoses, were determined
44 by International Classification of Diseases, 10th Revision (ICD10) coding system. COPD
45 was defined as J40-J44 in ICD-10 codes. Unique individuals with primary diagnosis of
46 COPD at index admission were identified. To guarantee accuracy of ICD10 coding,
47 diagnoses were ascertained by checking details in medical records.
48
49
50
51
52
53
54
55

56 **Hospital stays**

LOS was calculated as days by subtracting the admission date from discharge date at the index admission, which was the initial hospital stay. For patients readmitted frequently during study period, their initial hospital stays were included for analyses. If patients were discharged and readmitted on the same day, the readmissions were recorded as the same hospitalization as the initial one. LOS for the same-day discharge and readmission were calculated as the summed days of hospital stay in each consecutive admission.

Direct economic burden

Given the unavailability of data about days off from work due to COPD disabling effect, we only analysed direct health care expenditures during hospitalization. Information on total costs and patients' out-of-pocket costs were obtained and converted to U.S. dollars using annual currency exchange rate in 2017 (1 dollar=6.7518 yuan).²³

Potential factors

COPD is a complex disease involving airflow obstruction and multisystem diseases.²⁴ We combined secondary diagnoses to characterize COPD's concomitant diseases, including comorbidities and complications according to guidelines²⁵ and researches.^{24,26-28} Comorbidities were cardio/cerebro-vascular diseases, diabetes, respiratory infection, bronchiectasis, gastroesophageal reflux, obstructive sleep apnea syndrome (OSAS), lung cancer, depression or anxiety, and osteoporosis. Complications included respiratory failure, pulmonary heart diseases, hypoxemia, venous thromboembolism (VTE), pneumothorax and hypoxic-hypercarbic encephalopathy. As particulates in the air can trigger respiratory symptoms and lead to emergency visiting or hospitalization,²⁹⁻³¹ we analyzed ambient air pollutants on admission. Data on daily concentrations of particulate matter with a diameter of <2.5 μm (PM_{2.5}) and ozone were obtained from the Environment Monitoring Station nearest to the study site. Air pollutant concentrations change across

1
2
3 seasons. Given the potential impact of seasonal changes (temperatures, humidity),³² we
4 also took seasons into consideration. Emergency admission and day of week of admission
5 were analyzed as hospital factors. The weekday of admission was dichotomized into
6
7 Thursday-Sunday and Monday-Wednesday.
8
9
10

11 12 13 **Patient and public involvement**

14
15 Patients were not involved in this retrospective study.
16
17
18
19

20 **Statistics**

21
22 Data were summarized as number (percentage) for categorical variables and mean±SD
23 or median (interquartile ranges [IQR]) for continuous variables as appropriate. The
24 Wilcoxon rank sum test was adopted to compare LOS between patients with co-existing
25 morbidities and those without the morbid condition. To comprehensively analyze important
26 risk factors for longer LOS, we first developed a conceptual model using directed acyclic
27 graph (DAG). According to the model, baseline covariates were grouped into five blocks:
28 patient demographic characteristics, COPD complications, comorbidities, hospital and
29 environmental factors. Given the overdispersion in distribution of LOS, negative binomial
30 regression was modelled to estimate the effect of potential covariates on hospital stay in
31 each block. Rate ratios (RR, also known as relative risk) with 95% confidence interval (CI)
32 were reported for the changes in percent of association between covariates and LOS.
33
34 Then we fitted a final parsimonious model with significant variables obtained in
35 aforementioned models. Hospitalization costs among patients with different LOS were
36 compared using Kruskal-Wallis test. All statistical analyses were performed using SAS 9.4
37 (SAS Institute Inc., Cary, North Carolina, USA) with two-tailed $p < 0.05$.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 This study was approved by China-Japan Friendship Hospital Clinical Research
4 Ethics Committee (approval no. 2018-163-K119). Privacy and confidentiality of all patient's
5 information were maintained. Patient informed consent was not required.
6
7
8
9

10 11 **RESULTS**

12
13 Altogether, 565 new COPD patients were analyzed (Figure S1). The cohort had a mean
14 age of 69±11 years and 69.4% were male. Table 1 summarized the general information
15 of eligible patients. Respiratory failure (11.4%) and pulmonary heart diseases (10.7%)
16 were the top complications of COPD while cardiovascular or cerebrovascular diseases
17 (61.7%) was the most common comorbidity. Among the index admissions, 252 (44.6%)
18 admissions occurred on Thursday-Sunday. Outpatient departments were the main
19 source for COPD admissions, with 30.7% admissions from emergency. Inpatient
20 numbers were similar across seasons. Median exposure to ambient O₃ and PM_{2.5} were
21 92 ug/m³ and 52 ug/m³, respectively. LOS was 10 (IQR: 8-14) days and total
22 hospitalization cost was \$2080.7 (1501.6, 2877.17).
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 **Conceptual model for LOS**

38
39 A conceptual model was developed based on existing knowledge about COPD and its
40 LOS (Table S1).^{17,19,20,29-35} Figure 1 presented the links from individual-level characteristics,
41 health system-related factors, and environmental factors to LOS.
42
43
44
45
46
47

48 **Factors associated with LOS**

49
50 Based on the conceptual model, we grouped potential factors into five blocks: patient
51 demographic characteristics (age, gender), lung function and COPD complications,
52 comorbidities, hospital factors (emergency admission, weekday) and environmental
53 factors (season, ozone and PM_{2.5} at admission).
54
55
56
57
58
59
60

1
2
3 In single model with each block of factors, concomitant VTE (RR 1.38, 95% CI
4 1.07-1.76) and hypoxic-hypercarbic encephalopathy (RR 1.53, 95% CI 1.06-2.20) were
5 associated with an increased risk of longer stay. Lung function was negatively associated
6 with LOS with marginal insignificance. Respiratory infection (RR 1.12, 95% CI: 1.01-1.24),
7 osteoporosis (RR 1.45, 95% CI: 1.07-1.96), and emergence admission (RR 1.08, 95% CI:
8 1.01-1.16) emerged as significant risk factors for longer LOS. No significant associations
9 were observed regarding demographic and environmental factors (Table 2).

10
11
12 When comparing LOS in COPD patients with co-existing morbidities and those
13 without the morbid conditions, longer LOS was observed in patients with VTE than those
14 without VTE (16 vs 10 days, $p=0.0002$). In patients with osteoporosis, LOS was longer
15 compared to those without osteoporosis (15 vs 10 days, $p=0.0228$).

16
17
18 In final parsimonious analysis, concomitant VTE, hypoxic-hypercarbic
19 encephalopathy, respiratory infection, and osteoporosis remained significant for increased
20 risk in lengthy stay (all $P<0.05$) (Table 3).

21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 **COPD economic burden**

36 Patients having prolonged LOS were supposed to consume greater health resources. We
37 further analyzed the changes in COPD healthcare cost over LOS and observed an upward
38 trend in both total hospitalization cost and patients' out-of-pocket cost (both $P_{\text{trend}} < 0.0001$).
39 Figure 2 depicted the increase in costs among patients with LOS ≤ 8 days, 9-14 days, and
40 > 14 days divided by quantiles. Total costs in the three subgroups were \$1385.72 (1066.28,
41 1781.46), \$2177.73 (1779.58, 2650.42) and \$4104.61 (3124.56, 5233.09), respectively
42 ($p < 0.0001$). The corresponding figures for patients' out-of-pocket cost were \$701.16
43 (291.69, 1426.55), \$708.13 (329.97, 2130.87) and \$1124.53 (461.49, 3491.55)
44 ($p < 0.0001$).

DISCUSSION

COPD is costly and shortening hospital stay is one way to reduce its high economic burden. In this retrospective study involving nearly 600 COPD patients admitted between 2016 and 2017, we analyzed factors associated with LOS from multiple aspects, aiming to identify risk factors that could characterize high-risk population or determine early interventions that should be promptly delivered. COPD complications (VTE, hypoxic-hypercarbic encephalopathy) and comorbidities (respiratory infection and osteoporosis) were identified as important factors for prolonged LOS. Direct healthcare cost was in a graded increase with longer LOS.

Existing evidence on LOS in COPD patients showed a high heterogeneity and geographical variation.^{17,19,20,36-40} The analysis of COPD audit data across 13 European countries demonstrated an average LOS of 7 days in COPD patients.¹⁷ In a study of COPD comorbidity and LOS in US, mean LOS exceeded one week.⁴⁰ A real-life study in Norway showed a much longer LOS among patients admitted to rehabilitation unit, which were longer than 30 days.³⁹ In our study, the median LOS was 11 days. Risk factors for longer LOS also varied across different studies. Such variance are probably due to disparities in health systems in which patients are managed,¹⁷ diverse study population defined by different in/exclusion criteria, and various ways to deal with data, e.g., outcome definitions.^{19,39} In this study, there was a subgroup of patients who were discharged and readmitted immediately on the same day for the same cause of hospitalization. To reflect their real-life experience, we took the same-day discharge and readmission into consideration.

Co-existing morbidities have been mentioned as predictors of LOS.^{20,21} As shown in our data, VTE predicted longer LOS. It can be provoked by immobilization, heightened systemic inflammation, venous stasis or other factors that place COPD patients at risk of thrombosis.⁴⁰ Patients presenting lower limb swelling, dyspnea or other symptoms usually

1
2
3 undergo ultrasound or CT pulmonary angiogram for diagnosis. The additional
4 examinations and antithrombotic therapy can prolong their LOS. Likewise, hypoxic-
5 hypercarbic encephalopathy may contribute to the prolonged stay. It occurs when
6 neuronal damage is induced by oxygen and CO₂ retention and acidosis⁴¹, resulting in
7 physical impairment and coma, subsequently prolonging hospital stay. Respiratory
8 infections are a common trigger for COPD exacerbation. In our study, it was significantly
9 associated with LOS. The greater bacterial load and inflammation could delay patients'
10 recovery, which, in return, placed patients at greater likelihood of lengthy stay. In an
11 AECOPD study on infectious phenotypes,¹⁴ COPD patients with virus and/or bacteria
12 infection had longer LOS than non-infectious patients. Osteoporosis was another
13 contributor to lengthy stay. In GOLD 2020, osteoporosis is mentioned as a concomitant
14 chronic disease that influences COPD patients' hospitalizations.⁴² Some COPD-related
15 factors precipitate osteoporosis development, e.g., long-term inhaled corticosteroids use
16 for maintenance therapy^{40,43,44}, and lung function deterioration in disease progress.⁴⁵
17 Systematic inflammation and oxidative stress through sarcopenia in COPD can lead to
18 bone metabolic abnormalities and COPD-associated osteoporosis⁴⁵, placing COPD
19 patients at risk of fractures and longer stay.⁴⁶ The prolonged LOS in patients with
20 aforementioned concomitant diseases underscore the need for effective management of
21 COPD comorbidities and early prevention.

22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43 Additionally, we observed a monotonically increasing trend in both total
44 hospitalization cost and out-of-pocket cost over LOS, indicating longer hospital stay cost
45 more in COPD patients. The domestic and international studies concordantly showed that
46 COPD is a highly expensive disease and hospital-based care cost represents the major
47 cost driver.^{7,12} In 2016, COPD hospitalization cost was \$3669.33 per Chinese patient per
48 admission.¹⁰ In US, the cost accounted for over 70% of total COPD healthcare costs.¹⁹
49 The direct cost is estimated at \$72 billion annually¹¹ and is projected to be on the rise.^{11,12}

1
2
3 The substantial economic burden may be addressed through shortening hospital stay with
4 tailored interventions taken.
5

6
7 As shown in our study, COPD complications, (venous thromboembolism and
8 hypoxic-hypercarbic encephalopathy) and comorbidities (respiratory infection and
9 osteoporosis) increased risk of prolonged hospital stay. These comorbid conditions are
10 potentially preventable and treatable. For instance, early thromboprophylaxis like
11 anticoagulation or mechanical prophylaxis are adopted when COPD patients are admitted
12 to prevent thrombotic events during hospitalization; provide respiratory support promptly
13 when patients present hypoxic-hypercarbic syndrome; and recommend patients
14 pneumococcal and influenza vaccination to avoid respiratory infection. These tailored
15 interventions are expected to shorten LOS and save healthcare cost of COPD patients.
16
17

18
19
20
21
22
23
24
25
26 There were several strengths in our study. First, we provided clinical
27 epidemiological data on LOS and its risk factors in newly admitted patients for COPD.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

There were several strengths in our study. First, we provided clinical epidemiological data on LOS and its risk factors in newly admitted patients for COPD. Currently, studies on hospital stay are mainly restricted to developed countries.^{14,17-20,22,36,47,48} Our study demonstrated health care for Chinese COPD patients, including a comprehensive risk factor analysis for LOS and an increase of economic burden along with longer stay. Our study, together with the few prior studies in Chinese people,^{14,18} would help fill the gap in knowledge of COPD inpatients' LOS in developing countries. Second, we took the same-day discharge and readmission into consideration when analyzing the collected routinely data in daily clinical practice, which reflected real experiences of hospitalized patients in the real-world clinical setting. The identified risk factors could help determine early interventions to prevent excessive stay, which further reduce economic burden accrued over hospital stay. Hence, the findings are clinically relevant and have clinical implications. In addition, as the analyzed data were from electronic medical records, data collection process was standardized and all data were under scrutiny before entering into electronic system in hospital. Diagnoses of COPD and

1
2
3 other diseases were ascertained by reviewing medical records to ensure reliable data.
4
5 Fourth, the primary data analysis was based on conceptual model by the use of DAG,
6
7 which visually represented models in a graph with unidirectional arrows and made
8
9 assumptions about exposures' effects on LOS transparent and explicit⁴⁹. Thus, the
10
11 findings were theoretical model driven.
12

13
14 Hospital stay is a complex issue that is subject to patient, hospital and health
15
16 system factors. The underlying mechanisms have not been completely disentangled and
17
18 merit further investigations. The monotonically increasing hospitalization cost with LOS
19
20 underscores the great importance of shortening hospital stay in reducing COPD economic
21
22 burden, which may keep rising with the growing and aging population.
23

24
25 There were several limitations. First, the study was performed in NCRCD, one
26
27 of top hospitals in respiratory field in China. LOS may differ in patients admitted to
28
29 secondary hospitals or other health institutes that provide suboptimal care for respiratory
30
31 disease. This single-center study may not reflect the overall scenario of COPD
32
33 hospitalized patients. We could not analyze the average LOS among patients with
34
35 multiple rehospitalizations, which could reflect long-term disease burden of COPD. To
36
37 obtain a more comprehensive profile of hospital stay in Chinese COPD patients, it is
38
39 necessary to conduct a multi-center study with hospitals across different grades and
40
41 regions involved. A nation-wide network of health information system is recommended to
42
43 capture all hospitalizations and track the real-time dynamic admissions in COPD
44
45 patients. Second, we used hospitalization costs as a proxy for COPD economic burden
46
47 because information about patients' indirect costs were not available in this study. To
48
49 perform a profound analysis of COPD economic burden, indirect costs also need to be
50
51 evaluated. Further study on COPD economic burden should take both direct and indirect
52
53 costs into consideration in the future.
54
55
56
57
58
59
60

CONCLUSION

This study underscores the significance of concomitant morbidities and disease severity in predicting COPD hospital stay. Healthcare cost increased over hospital stay. Identification of high-risk patients for excess stay and delivery of early interventions such as thromboprophylaxis may offer one way to shorten LOS in COPD patients, which would help reduce the economic burden accrued over the stay.

For peer review only

1
2
3 **Acknowledgements** we thank hospital's administrative and finance departments for
4
5 their help with data collection.
6

7
8 **Author Contributions** T.Y., J.J.J., C.W. were involved in conceptualization, funding
9
10 acquisition and supervision. F.D., Y.Y.W., Y.L., X.S.L. collected data. F.D., X.X.R., K.H.
11
12 analyzed and interpreted the data. F.D. wrote the draft of manuscript: T.Y., J.J.J., F.D.,
13
14 C.W., K.H., X.X.R., S.W.Q, H.T.N., Y.Y.W., Y.L., M.Y.L., X.S.L. contributed to writing-
15
16 review and approved the final manuscript.
17

18
19 **Funding** This study was supported by National Key R&D Program of China
20
21 (2016YFC0206502), National Key R&D Program of China (2016YFC1303900), CAMS
22
23 Innovation Fund for Medical Sciences (CIFMS) (2018-I2M-1-001), and Science
24
25 Foundation of China-Japan Friendship Hospital for junior researchers (2017-1-QN-3).
26

27
28 **Disclaimer** No conflicts of interest are involved in this manuscript.
29

30
31 **Competing interests** None declared
32

33
34 **Patient consent for publication** Not required
35

36
37 **Ethics approval** We obtained approval from the China-Japan Friendship Hospital Clinical
38
39 Research Ethics Committee (approval no. 2018-163-K119). Privacy and confidentiality of
40
41 all patient's information were maintained. Patient informed consent was not required.
42

43
44 **Data sharing statement** No additional data are available
45

46
47 **Availability of data and material:** Not applicable
48

49
50 **Code availability:** Not applicable
51
52
53
54
55
56
57

REFERENCES

1. Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet (London, England)*. 2019;394(10204):1145-1158.
2. Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. *Lancet (London, England)*. 2018;391(10131):1706-1717.
3. Viniol C, Vogelmeier CF. Exacerbations of COPD. *European respiratory review : an official journal of the European Respiratory Society*. 2018;27(147).
4. Lareau S, Moseson E, Slatore CG. Exacerbation of COPD. *American journal of respiratory and critical care medicine*. 2018;198(11):P21-p22.
5. Donaldson GC, Wedzicha JA. COPD exacerbations .1: Epidemiology. *Thorax*. 2006;61(2):164-168.
6. Chen X, Wang N, Chen Y, Xiao T, Fu C, Xu B. Costs of chronic obstructive pulmonary disease in urban areas of China: a cross-sectional study in four cities. *International journal of chronic obstructive pulmonary disease*. 2016;11:2625-2632.
7. Zhu B, Wang Y, Ming J, Chen W, Zhang L. Disease burden of COPD in China: a systematic review. *International journal of chronic obstructive pulmonary disease*. 2018;13:1353-1364.
8. Fang X, Wang X, Bai C. COPD in China: the burden and importance of proper management. *Chest*. 2011;139(4):920-929.
9. He QY, Zhou X, Xie CM, Liang ZA, Chen P, Wu CG. [Impact of chronic obstructive pulmonary disease on quality of life and economic burden in Chinese urban areas]. *Zhonghua jie he he hu xi za zhi = Chinese journal of tuberculosis and respiratory diseases*. 2009;32(4):253-257.

- 1
2
3 10. Li M, Wang F, Chen R, et al. Factors contributing to hospitalization costs for patients
4 with COPD in China: a retrospective analysis of medical record data. *International*
5 *journal of chronic obstructive pulmonary disease*. 2018;13:3349-3357.
6
7
8
- 9 11. Khakban A, Sin DD, FitzGerald JM, et al. The Projected Epidemic of Chronic
10 Obstructive Pulmonary Disease Hospitalizations over the Next 15 Years. A
11 Population-based Perspective. *American journal of respiratory and critical care*
12 *medicine*. 2017;195(3):287-291.
13
14
15
- 16 12. Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of
17 chronic obstructive pulmonary disease in the USA. *ClinicoEconomics and outcomes*
18 *research : CEOR*. 2013;5:235-245.
19
20
21
- 22 13. Ramsey SD, Hobbs FD. Chronic obstructive pulmonary disease, risk factors, and
23 outcome trials: comparisons with cardiovascular disease. *Proceedings of the*
24 *American Thoracic Society*. 2006;3(7):635-640.
25
26
27
- 28 14. Dai MY, Qiao JP, Xu YH, Fei GH. Respiratory infectious phenotypes in acute
29 exacerbation of COPD: an aid to length of stay and COPD Assessment Test.
30 *International journal of chronic obstructive pulmonary disease*. 2015;10:2257-2263.
31
32
33
- 34 15. Chen YH, Yao WZ, Cai BQ, et al. Economic analysis in admitted patients with acute
35 exacerbation of chronic obstructive pulmonary disease. *Chinese medical journal*.
36 2008;121(7):587-591.
37
38
39
- 40 16. Ford ES. Hospital discharges, readmissions, and ED visits for COPD or
41 bronchiectasis among US adults: findings from the nationwide inpatient sample
42 2001-2012 and Nationwide Emergency Department Sample 2006-2011. *Chest*.
43 2015;147(4):989-998.
44
45
46
- 47 17. Ruparel M, Lopez-Campos JL, Castro-Acosta A, Hartl S, Pozo-Rodriguez F,
48 Roberts CM. Understanding variation in length of hospital stay for COPD
49 exacerbation: European COPD audit. *ERJ open research*. 2016;2(1).
50
51
52

- 1
2
3 18. Ko FWS, Chan KP, Ngai J, et al. Blood eosinophil count as a predictor of hospital
4 length of stay in COPD exacerbations. *Respirology (Carlton, Vic)*. 2020;25(3):259-
5 266.
6
7
8
9
10 19. Wang Y, Stavem K, Dahl FA, Humerfelt S, Haugen T. Factors associated with a
11 prolonged length of stay after acute exacerbation of chronic obstructive pulmonary
12 disease (AECOPD). *International journal of chronic obstructive pulmonary disease*.
13 2014;9:99-105.
14
15
16
17 20. Harries TH, Thornton HV, Crichton S, Schofield P, Gilkes A, White PT. Length of
18 stay of COPD hospital admissions between 2006 and 2010: a retrospective
19 longitudinal study. *International journal of chronic obstructive pulmonary disease*.
20 2015;10:603-611.
21
22
23
24
25 21. Roberts CM, Stone RA, Lowe D, Pursey NA, Buckingham RJ. Co-morbidities and
26 90-day outcomes in hospitalized COPD exacerbations. *Copd*. 2011;8(5):354-361.
27
28
29
30 22. Limsuwat C, Mankongpaisarnrung C, Dumrongmongcolgul N, Nugent K. Factors
31 influencing the length of hospital stay in patients with acute exacerbations of chronic
32 obstructive pulmonary disease admitted to intensive care units. *Quality*
33 *management in health care*. 2014;23(2):86-93.
34
35
36
37
38 23. National Bureau of Statistics. Available from:
39 http://www.stats.gov.cn/tjsj/zxfb/201802/t20180228_1585631.html. Accessed
40 December 1, 2019.
41
42
43
44 24. Sethi S. Infection as a comorbidity of COPD. *The European respiratory journal*.
45 2010;35(6):1209-1215.
46
47
48
49 25. Celli BR, Decramer M, Wedzicha JA, et al. An official American Thoracic
50 Society/European Respiratory Society statement: research questions in COPD.
51 *European respiratory review : an official journal of the European Respiratory*
52 *Society*. 2015;24(136):159-172.
53
54
55
56
57
58
59
60

- 1
2
3 26. Cavailles A, Brinchault-Rabin G, Dixmier A, et al. Comorbidities of COPD. *European*
4 *respiratory review : an official journal of the European Respiratory Society.*
5
6 *2013;22(130):454-475.*
7
8
9 27. Garcia-Olmos L, Alberquilla A, Ayala V, et al. Comorbidity in patients with chronic
10 obstructive pulmonary disease in family practice: a cross sectional study. *BMC*
11 *family practice.* 2013;14:11.
12
13
14 28. Guerrero M, Crisafulli E, Liapikou A, et al. Readmission for Acute Exacerbation
15 within 30 Days of Discharge Is Associated with a Subsequent Progressive Increase
16 in Mortality Risk in COPD Patients: A Long-Term Observational Study. *PloS one.*
17 *2016;11(3):e0150737.*
18
19
20 29. Ling SH, van Eeden SF. Particulate matter air pollution exposure: role in the
21 development and exacerbation of chronic obstructive pulmonary disease.
22 *International journal of chronic obstructive pulmonary disease.* 2009;4:233-243.
23
24
25 30. Li J, Sun S, Tang R, et al. Major air pollutants and risk of COPD exacerbations: a
26 systematic review and meta-analysis. *International journal of chronic obstructive*
27 *pulmonary disease.* 2016;11:3079-3091.
28
29
30 31. Anderson JO, Thundiyil JG, Stolbach A. Clearing the air: a review of the effects of
31 particulate matter air pollution on human health. *Journal of medical toxicology :*
32 *official journal of the American College of Medical Toxicology.* 2012;8(2):166-175.
33
34
35 32. Donaldson GC, Wedzicha JA. The causes and consequences of seasonal variation
36 in COPD exacerbations. *International journal of chronic obstructive pulmonary*
37 *disease.* 2014;9:1101-1110.
38
39
40 33. Hillas G, Perlikos F, Tsiligianni I, Tzanakis N. Managing comorbidities in COPD.
41 *International journal of chronic obstructive pulmonary disease.* 2015;10:95-109.
42
43
44 34. Eccles R. An explanation for the seasonality of acute upper respiratory tract viral
45 infections. *Acta oto-laryngologica.* 2002;122(2):183-191.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 35. Parappil A, Depczynski B, Collett P, Marks GB. Effect of comorbid diabetes on
4 length of stay and risk of death in patients admitted with acute exacerbations of
5 COPD. *Respirology (Carlton, Vic)*. 2010;15(6):918-922.
6
7
8
9 36. Agboado G, Peters J, Donkin L. Factors influencing the length of hospital stay
10 among patients resident in Blackpool admitted with COPD: a cross-sectional study.
11 *BMJ open*. 2012;2(5).
12
13
14
15 37. Holland M, Alkhalil M, Chandromouli S, Janjua A, Babores M. Eosinopenia as a
16 marker of mortality and length of stay in patients admitted with exacerbations of
17 chronic obstructive pulmonary disease. *Respirology (Carlton, Vic)*. 2010;15(1):165-
18 167.
19
20
21
22
23 38. Ingadottir AR, Beck AM, Baldwin C, et al. Association of energy and protein intakes
24 with length of stay, readmission and mortality in hospitalised patients with chronic
25 obstructive pulmonary disease. *The British journal of nutrition*. 2018;119(5):543-551.
26
27
28
29 39. Vitacca M, Marino S, Comini L, Fezzardi L, Paneroni M. Bacterial Colonization in
30 COPD Patients Admitted to a Rehabilitation Respiratory Unit and Impact on Length
31 of Stay: A Real-Life Study. *Copd*. 2018;15(6):581-587.
32
33
34
35 40. Inabnit LS, Blanchette C, Ruban C. Comorbidities and length of stay in chronic
36 obstructive pulmonary disease patients. *Copd*. 2018;15(4):355-360.
37
38
39
40 41. J Han, F Zeng, S Cheng, Z Gong, Zhou Y. The Role of Neurous Autophagy in
41 Pulmonary Encephalopathy and Signaling Pathways. *West Indian Medical Journal*.
42 2015.
43
44
45
46 42. Global strategy for the diagnosis, management and prevention of chronic
47 obstructive pulmonary disease 2020 report [EB/OL] (2019-11-05) [Accessed April
48 12, 2020]. <https://goldcopd.org/gold-reports/>.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 43. Waljee AK, Rogers MA, Lin P, et al. Short term use of oral corticosteroids and
4 related harms among adults in the United States: population based cohort study.
5
6 *BMJ (Clinical research ed)*. 2017;357:j1415.
7
8
9
10 44. Jorgensen NR, Schwarz P, Holme I, Henriksen BM, Petersen LJ, Backer V. The
11 prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a
12 cross sectional study. *Respiratory medicine*. 2007;101(1):177-185.
13
14
15 45. Okazaki R, Watanabe R, Inoue D. Osteoporosis Associated with Chronic
16 Obstructive Pulmonary Disease. *J Bone Metab*. 2016;23(3):111-120.
17
18
19 46. Papaioannou A, Adachi JD, Parkinson W, Stephenson G, Bedard M. Lengthy
20 hospitalization associated with vertebral fractures despite control for comorbid
21 conditions. *Osteoporos Int*. 2001;12(10):870-874.
22
23
24
25 47. Rinne ST, Wong ES, Hebert PL, et al. Weekend Discharges and Length of Stay
26 Among Veterans Admitted for Chronic Obstructive Pulmonary Disease. *Medical*
27 *care*. 2015;53(9):753-757.
28
29
30
31 48. Quintana JM, Unzurrunzaga A, Garcia-Gutierrez S, et al. Predictors of Hospital
32 Length of Stay in Patients with Exacerbations of COPD: A Cohort Study. *Journal of*
33 *general internal medicine*. 2015;30(6):824-831.
34
35
36
37 49. Lederer DJ, Bell SC, Branson RD, et al. Control of Confounding and Reporting of
38 Results in Causal Inference Studies. Guidance for Authors from Editors of
39 Respiratory, Sleep, and Critical Care Journals. *Annals of the American Thoracic*
40 *Society*. 2019;16(1):22-28.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Characteristics of patients hospitalized for COPD

	Study patients N=565	Values ^a
Demographic	Age, years	69±11
characteristics	Men	392 (69.4)
	Married	544 (96.3)
	Local resident	361 (63.9)
Lung function and complications ^b	Pre-FEV1	1.16 (0.84, 1.73)
	Respiratory failure	63 (11.4)
	Pulmonary heart diseases	59 (10.7)
	Hypoxemia	10 (1.8)
	VTE	9 (1.6)
	Pneumothorax	2 (0.4)
	Hypoxic-hypercarbic encephalopathy	4 (0.7)
Comorbidities ^b	Cardio/Cerebrovascular Diseases	340 (61.7)
	Diabetes	102 (18.5)
	Respiratory infection	67 (12.2)
	Bronchiectasis	47 (8.5)
	Reflux esophagitis	38 (6.9)
	OSAS	18 (3.3)
	Lung cancer	5 (0.9)
	Anxiety depression	12 (2.2)
	Osteoporosis	6 (1.1)
Admission	Obesity	56 (9.9)
	Admitted on Thursday-Sunday	252 (44.6)
	Admitted from emergency	173 (30.7)

Study patients N=565		Values ^a
Seasons at admission	March-May	164 (29.0)
	June-August	145 (25.7)
	Sep.-Nov.	94 (16.6)
	Dec.-Feb.	162 (28.7)
Air pollution at admission	O ₃ , ug/m ³	92 (63, 150)
	PM _{2.5} , ug/m ³	52 (25, 88)
Hospital stay and healthcare cost	Length of stay, days	10 (8, 14)
	Direct cost of hospitalization, \$	2080.7 (1501.6, 2877.17)

^a Data were represented as mean ± SD or median (Interquartile) for continuous variables where appropriate and n (%) for categorical variables.

^b Fourteen patients' complications and comorbidities were missing due to their unavailable data on secondary diagnoses.

Table 2. Single model analysis for factors associated with hospital stay at index admission based on DAG

Block	Variable	RR 95%CI	P value	
Demographic characteristics	Age, per 5 years	1.02 (1.00-1.03)	0.032	
	Male	1.04 (0.96-1.12)	0.312	
Lung function and complications	FEV1	0.97 (0.95-1.00)	0.055	
	Respiratory failure	1.05 (0.94-1.18)	0.396	
	Pulmonary heart diseases	1.03 (0.92-1.16)	0.624	
	Hypoxemia	0.96 (0.74-1.24)	0.757	
	VTE	1.38 (1.07-1.76)	0.012*	
	Pneumothorax	1.63 (0.98-2.70)	0.057	
	Hypoxic-hypercarbic encephalopathy	1.53 (1.06-2.20)	0.023*	
	COPD comorbidities	Cardio/Cerebrovascular Diseases	1.05 (0.98-1.13)	0.184
		Diabetes	0.98 (0.90-1.07)	0.648
		Respiratory infection	1.12 (1.01-1.24)	0.035*
Bronchiectasis		1.00 (0.88-1.13)	0.967	
Reflux esophagitis		1.00 (0.88-1.15)	0.959	
OSAS		1.17 (0.97-1.42)	0.094	
Lung cancer		1.09 (0.77-1.57)	0.620	
Anxiety depression		0.89 (0.69-1.13)	0.324	
Hospital factors	Osteoporosis	1.45 (1.07-1.96)	0.018*	
	Obesity	0.97 (0.86-1.08)	0.559	
	Admitted on Thursday-Sunday	1.04 (0.97-1.11)	0.319	
Environmental factors	Admitted from emergency	1.08 (1.01-1.16)	0.033*	
	Season at admission, Mar.-May	1.01 (0.91-1.12)	0.850	
	Season at admission, Jun.-Aug.	1.08 (0.96-1.22)	0.176	

Block	Variable	RR 95%CI	P value
	Season at admission, Sep.-Nov.	0.98 (0.88-1.09)	0.752
	O3, per 10 ug/m ³	1.00 (0.995-1.01)	0.573
	PM2.5, per 10 ug/m ³	1.00 (0.998-1.01)	0.217

^a $P < 0.05$

For peer review only

Table 3. Parsimonious analysis for factors associated with hospital stay at index admission

Variable	RR 95%CI	P value
Age, per 5 years	1.01 (0.997-1.03)	0.126
Pre-FEV1	0.97 (0.95-1.00)	0.055
VTE	1.40 (1.09-1.78)	0.007*
Hypoxic-hypercarbic encephalopathy	1.53 (1.07-2.18)	0.020*
Respiratory infection	1.11 (1.01-1.23)	0.040*
Osteoporosis	1.42 (1.05-1.91)	0.021*
Emergency admission	1.06 (0.98-1.14)	0.147

^a $P < 0.05$

1
2
3 **Figure 1. Conceptual model using directed acyclic graph (DAG) for factors**
4 **associated with hospital stay**
5

6
7 Based on current knowledge on COPD risk factors, we developed a conceptual model
8 using DAG. Potential covariates at baseline were grouped into five blocks: patient
9 demographic characteristics (age, gender), COPD complications, comorbidities, hospital
10 factors (emergency admission, weekday of admission) and environmental factors
11 (season, ozone and PM_{2.5} at admission).
12
13
14
15
16
17
18
19

20 **Figure 2. COPD costs during hospitalization**
21

22 During hospitalization, total cost and the out-of-pocket cost were compared among
23 patients with LOS ≤8 days, 9-14 days, and >14 days according to quartiles of LOS. The
24 costs increased with longer LOS ($P_{\text{trend}} < 0.0001$ for both total cost and the out-of-pocket
25 cost).
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Conceptual model using directed acyclic graph (DAG) for factors associated with hospital stay. Based on current knowledge on COPD risk factors, we developed a conceptual model using DAG. Potential covariates at baseline were grouped into five blocks: patient demographic characteristics (age, gender), COPD complications, comorbidities, hospital factors (emergency admission, weekday of admission) and environmental factors (season, ozone and PM2.5 at admission).

122x104mm (900 x 900 DPI)




Figure 2. COPD costs during hospitalization
 During hospitalization, total cost and the out-of-pocket cost were compared among patients with LOS ≤8 days, 9-14 days, and >14 days according to quartiles of LOS. The costs increased with longer LOS (Ptrend <0.0001 for both total cost and the out-of-pocket cost).

228x152mm (300 x 300 DPI)

SUPPLEMENTARY INFORMATION

Factors Associated with Inpatient Length of Stay among Hospitalized Patients with Chronic Obstructive Pulmonary Disease, China, 2016-2017: a retrospective study

Fen Dong¹, Ke Huang², Xiaoxia Ren², Shiwei Qumu², Hongtao Niu², Yanyan Wang³,

Yong Li², Minya Lu⁴, Xinshan Lin^{2,5}, Ting Yang^{2*}, Jianjun Jiao^{6*}, Chen Wang^{2,7}

***Co-corresponding authors:** Ting Yang and Jianjun Jiao contributed equally to this paper as co-corresponding authors.

Affiliations:

¹Institute of Clinical Medical Sciences, China–Japan Friendship Hospital, Beijing, China;

²Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Chinese Academy of Medical Science, Beijing, China;

³Department of Medical Records, China–Japan Friendship Hospital, Beijing, China;

⁴Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China;


⁵Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China;

⁶Department of Medical Administration, China–Japan Friendship Hospital, Beijing, China;

⁷Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

1
2
3
4 **Supplementary** Figure S1- Flow chart of data cleaning process

5 **Supplementary** Table S1- Observational studies on LOS and risk factors in patients
6 admitted for COPD
7
8
9



45 **Figure S1- Flow chart of data cleaning process**
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table S1. Observational studies on LOS and risk factors in patients admitted for COPD ^a

Countries/regions	Years for LOS	Study patients	LOS	Risk factors for longer LOS
Thirteen European counties ¹	Oct.-Dec.2010; Jan.-Feb. 2011	Exacerbated COPD patients in Europe	Median (IQR): 7 (4-11) days	Clinical severity, treatment
UK ²⁻⁵	2006-2010	COPD patients registered with London general practitioners aged ≥45 years	Mean: 8.2 days in 2006 and 7 days in 2010	Age, hospital and community factors
	Apr.1st, 2005- Mar.31st, 2010	COPD patients aged ≥40 years in Blackpool, UK	Median: 6 days Mean: 9.8 days	Age, deprivation, Charlson index, specialty of admission, and cause of exacerbations
	Mar. 2007- Apr. 2008	65 AECOPD patients	Median: 5 (1-27) in normal eosinophils and 8 (2-61) in eosinopenia	Eosinopenia
	Mar. 2015-Mar. 2016	99 COPD patients admitted to department of pulmonary medicine at Landspítali National University hospital	9 days	No clear association between energy or protein intake and LOS
Norway ⁶	March 2006-December 2008	Patients discharged after COPD at Oslo University hospital in Norway	Median: 6 (3.5-11) days	Admission between Thursday and Saturday, heart failure, diabetes, stroke, high arterial PCO ₂ , and low serum albumin level were associated with LOS>11 days. ^b

Countries/regions	Years for LOS	Study patients	LOS	Risk factors for longer LOS
Italy ⁷	2010	269 COPD patients in a respiratory rehabilitation unit in Italy	Mean \pm SD: 31 \pm 17 days	Comorbidity, age, invasive procedure, disability, admission provenance predicted longer stay (\geq 30 days) ^b
Portugal ⁸	Jan-Jun., 2016	242 diabetic patients with AECOPD or community acquired pneumonia	Median: 10 days (min-max, 1-66)	LOS was positively correlated with glycemic variability
Spain ⁹	Jun. 2008-Sep. 2010	AECOPD patients visiting emergency department in Spain	-	Baseline dyspnea, physical activity level, and hospital variability
US ^{10,11}	Jan. 1st, -Dec. 31st, 2016	3399 COPD patients with LOS \leq 60 days in Premier healthcare database	Mean \pm SD: 11.64 \pm 9.40 days	Comorbidity (congestive heart failure, fluid and electrolyte disorders, renal failure) were associated with longer stay
	Oct. 1st, 2008- Sep. 30th, 2010	25301 COPD patients admitted to veteran affairs health care system	Mean \pm SD: 4.2 \pm 2.7 days for weekend discharged patients, 5.4 \pm 4.9 days for weekday discharged patients	Fewer weekend discharges was associated with longer stay.
Australia ¹²	2007	172 AECOPD patients	7.8 days in patients with diabetes, 6.5 days in patients without diabetes	Patients with diabetes had increased LOS, but differences were not statistically significant after adjustment for covariates.
China ^{13,14}	Mar. 2013-Aug.2016	346 AECOPD patients in a tertiary hospital in Hongkong, China	Median (IQR): 5 (7) days	An eosinophil value of $<0.144 \times 10^9/L$ on admission or $<2\%$ was associated with

Countries/regions	Years for LOS	Study patients	LOS	Risk factors for longer LOS
	January-June, 2014	81 exacerbated COPD patients in a hospital in Anhui, China	Mean \pm SD: 9.6 \pm 4.1 days	longer hospital LOS (\geq 5 days) for AECOPD ^b Respiratory infection was associated with LOS

^a we conducted a literature review by searching literatures in the following database: Medline, Embase, Pubmed and Web of Science. We searched observational studies that focused on risk factors of longer hospital stay at index admission in COPD inpatients. Terms used in search were: "Chronic obstructive pulmonary disease", "COPD", "hospitalization", "length of stay", "LOS", and "hospital stay". Published years ranged from 2000 to 2019. Study types included prospective study, retrospective study, cohort analysis or observational study. We also searched the references in retrieved papers for supplement studies that may be missed during the search

^b In risk factor analysis, LOS was categorized into a binary variable.^{6,7,13}

AECOPD=acute exacerbation of COPD; UK=United Kingdom; US=United States

References

1. Ruparel M, Lopez-Campos JL, Castro-Acosta A, Hartl S, Pozo-Rodriguez F, Roberts CM. Understanding variation in length of hospital stay for COPD exacerbation: European COPD audit. *ERJ open research*. 2016;2(1).
2. Harries TH, Thornton HV, Crichton S, Schofield P, Gilkes A, White PT. Length of stay of COPD hospital admissions between 2006 and 2010: a retrospective longitudinal study. *International journal of chronic obstructive pulmonary disease*. 2015;10:603-611.

3. Agboado G, Peters J, Donkin L. Factors influencing the length of hospital stay among patients resident in Blackpool admitted with COPD: a cross-sectional study. *BMJ open*. 2012;2(5).
4. Holland M, Alkhalil M, Chandromouli S, Janjua A, Babores M. Eosinopenia as a marker of mortality and length of stay in patients admitted with exacerbations of chronic obstructive pulmonary disease. *Respirology (Carlton, Vic)*. 2010;15(1):165-167.
5. Ingadottir AR, Beck AM, Baldwin C, et al. Association of energy and protein intakes with length of stay, readmission and mortality in hospitalised patients with chronic obstructive pulmonary disease. *The British journal of nutrition*. 2018;119(5):543-551.
6. Wang Y, Stavem K, Dahl FA, Humerfelt S, Haugen T. Factors associated with a prolonged length of stay after acute exacerbation of chronic obstructive pulmonary disease (AECOPD). *International journal of chronic obstructive pulmonary disease*. 2014;9:99-105.
7. Vitacca M, Marino S, Comini L, Fezzardi L, Paneroni M. Bacterial Colonization in COPD Patients Admitted to a Rehabilitation Respiratory Unit and Impact on Length of Stay: A Real-Life Study. *Copd*. 2018;15(6):581-587.
8. Ferreira L, Moniz AC, Carneiro AS, et al. The impact of glycemic variability on length of stay and mortality in diabetic patients admitted with community-acquired pneumonia or chronic obstructive pulmonary disease. *Diabetes & metabolic syndrome*. 2019;13(1):149-153.
9. Quintana JM, Unzurrunzaga A, Garcia-Gutierrez S, et al. Predictors of Hospital Length of Stay in Patients with Exacerbations of COPD: A Cohort Study. *Journal of general internal medicine*. 2015;30(6):824-831.
10. Inabnit LS, Blanchette C, Ruban C. Comorbidities and length of stay in chronic obstructive pulmonary disease patients. *Copd*. 2018;15(4):355-360.
11. Rinne ST, Wong ES, Hebert PL, et al. Weekend Discharges and Length of Stay Among Veterans Admitted for Chronic Obstructive Pulmonary Disease. *Medical care*. 2015;53(9):753-757.
12. Parappil A, Depczynski B, Collett P, Marks GB. Effect of comorbid diabetes on length of stay and risk of death in patients admitted with acute exacerbations of COPD. *Respirology (Carlton, Vic)*. 2010;15(6):918-922.
13. Ko FWS, Chan KP, Ngai J, et al. Blood eosinophil count as a predictor of hospital length of stay in COPD exacerbations. *Respirology (Carlton, Vic)*. 2020;25(3):259-266.

- 1
2
3
4
5 14. Dai MY, Qiao JP, Xu YH, Fei GH. Respiratory infectious phenotypes in acute exacerbation of COPD: an aid to length of stay and COPD
6 Assessment Test. *International journal of chronic obstructive pulmonary disease*. 2015;10:2257-2263.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

For peer review only

Reporting checklist for cohort study.

Based on the STROBE cohort guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the STROBE cohort reporting guidelines, and cite them as:

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

	Reporting Item	Page Number
Title and abstract		
Title	#1a Indicate the study's design with a commonly used term in the title or the abstract	1
Abstract	#1b Provide in the abstract an informative and	3

1			balanced summary of what was done and what	
2			was found	
3				
4				
5				
6	Introduction			
7				
8				
9	Background /	#2	Explain the scientific background and rationale	5
10	rationale		for the investigation being reported	
11				
12				
13				
14	Objectives	#3	State specific objectives, including any	6
15			prespecified hypotheses	
16				
17				
18				
19	Methods			
20				
21				
22				
23	Study design	#4	Present key elements of study design early in	6
24			the paper	
25				
26				
27				
28	Setting	#5	Describe the setting, locations, and relevant	6
29			dates, including periods of recruitment,	
30			exposure, follow-up, and data collection	
31				
32				
33				
34				
35	Eligibility criteria	#6a	Give the eligibility criteria, and the sources and	6
36			methods of selection of participants. Describe	
37			methods of follow-up.	
38				
39				
40				
41				
42				
43	Eligibility criteria	#6b	For matched studies, give matching criteria and	n/a
44			number of exposed and unexposed	
45				
46				
47				
48	Variables	#7	Clearly define all outcomes, exposures,	7-8
49			predictors, potential confounders, and effect	
50			modifiers. Give diagnostic criteria, if applicable	
51				
52				
53				
54				
55				
56	Data sources /	#8	For each variable of interest give sources of	6-8
57				
58				
59				
60				

1	measurement		data and details of methods of assessment	
2			(measurement). Describe comparability of	
3			assessment methods if there is more than one	
4			group. Give information separately for for	
5			exposed and unexposed groups if applicable.	
6				
7				
8				
9				
10				
11				
12	Bias	#9	Describe any efforts to address potential	6
13			sources of bias	
14				
15				
16				
17				
18	Study size	#10	Explain how the study size was arrived at	n/a. In this
19				retrospectively
20				cohort, patients
21				were
22				consecutively
23				admitted
24				
25				
26				
27				
28				
29				
30				
31				
32	Quantitative	#11	Explain how quantitative variables were	7-8
33	variables		handled in the analyses. If applicable, describe	
34			which groupings were chosen, and why	
35				
36				
37				
38				
39				
40	Statistical	#12a	Describe all statistical methods, including those	8
41	methods		used to control for confounding	
42				
43				
44				
45	Statistical	#12b	Describe any methods used to examine	n/a. In this study,
46	methods		subgroups and interactions	we studied
47				potential factors
48				related to length
49				of stay in COPD
50				patients
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

1	Statistical	#12c	Explain how missing data were addressed	23-24 Table 1
2				
3	methods			
4				
5				
6	Statistical	#12d	If applicable, explain how loss to follow-up was	
7				
8	methods		addressed	
9				
10				
11	Statistical	#12e	Describe any sensitivity analyses	
12				
13	methods			
14				
15				
16				
17	Results			
18				
19				
20	Participants	#13a	Report numbers of individuals at each stage of	9 Figure S1
21			study—eg numbers potentially eligible,	
22			examined for eligibility, confirmed eligible,	
23			included in the study, completing follow-up,	
24			and analysed. Give information separately for	
25			for exposed and unexposed groups if	
26			applicable.	
27				
28				
29				
30				
31				
32				
33				
34				
35				
36				
37	Participants	#13b	Give reasons for non-participation at each	9 Figure S1
38			stage	
39				
40				
41				
42	Participants	#13c	Consider use of a flow diagram	9 Figure S1
43				
44				
45	Descriptive data	#14a	Give characteristics of study participants (eg	9, 23-24 Table 1
46			demographic, clinical, social) and information	
47			on exposures and potential confounders. Give	
48			information separately for exposed and	
49			unexposed groups if applicable.	
50				
51				
52				
53				
54				
55				
56				
57	Descriptive data	#14b	Indicate number of participants with missing	23-24 Table 1
58				
59				
60				

data for each variable of interest

1			
2			
3			
4	Descriptive data	#14c Summarise follow-up time (eg, average and	7, hospital stay at
5		total amount)	the initial
6			admission was
7			the follow-up
8			time
9			
10			
11			
12			
13			
14			
15	Outcome data	#15 Report numbers of outcome events or	9, 23-24 Table 1
16		summary measures over time. Give information	
17		separately for exposed and unexposed groups	
18		if applicable.	
19			
20			
21			
22			
23			
24			
25	Main results	#16a Give unadjusted estimates and, if applicable,	10, 25-27 Table
26		confounder-adjusted estimates and their	2-3
27		precision (eg, 95% confidence interval). Make	
28		clear which confounders were adjusted for and	
29		why they were included	
30			
31			
32			
33			
34			
35			
36			
37			
38	Main results	#16b Report category boundaries when continuous	10 Figure 2
39		variables were categorized	
40			
41			
42			
43	Main results	#16c If relevant, consider translating estimates of	n/a. Relative risk
44		relative risk into absolute risk for a meaningful	was the main
45		time period	indicator for
46			length of stay in
47			this paper
48			
49			
50			
51			
52			
53			
54			
55	Other analyses	#17 Report other analyses done—e.g., analyses of	n/a. This study
56		subgroups and interactions, and sensitivity	focused on the
57			
58			
59			
60			

analyses

potential factors

associated with

prolonged

hospital stay in

COPD patients

Discussion

Key results	#18	Summarise key results with reference to study objectives	11
Limitations	#19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias.	14
Interpretation	#20	Give a cautious overall interpretation considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence.	11-12, 14
Generalisability	#21	Discuss the generalisability (external validity) of the study results	13-14
Other Information			
Funding	#22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present	16

1 article is based
2
3

4 None The STROBE checklist is distributed under the terms of the Creative Commons Attribution
5 License CC-BY. This checklist can be completed online using <https://www.goodreports.org/>, a tool
6 made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60